Page 1 of 113

DOE Review Release 08/27/2020

Internal Dosimetry Co-Exposure Data for Los 

Alamos National Laboratory

ORAUT-OTIB-0062 Rev. 01

Effective Date: 09/01/2020

Supersedes: Revision 00

Subject Expert(s): Matthew G. Arno

Document Owner 

Approval: Signature on File

Matthew G. Arno, Document Owner

Approval Date: 03/09/2020

Concurrence: Signature on File

John M. Byrne, Objective 1 Manager

Concurrence Date: 03/10/2020

Concurrence: Signature on File

Scott R. Siebert, Objective 3 Manager

Concurrence Date: 03/07/2020

Concurrence: Vickie S. Short Signature on File for

Kate Kimpan, Project Director

Concurrence Date: 03/09/2020

Approval: Signature on File

Timothy D. Taulbee, Associate Director for Science

Approval Date: 08/05/2020

FOR DOCUMENTS MARKED AS A TOTAL REWRITE, REVISION, OR PAGE CHANGE, REPLACE THE PRIOR 

REVISION AND DISCARD / DESTROY ALL COPIES OF THE PRIOR REVISION.

New Total Rewrite Revision Page Change
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 2 of 113

PUBLICATION RECORD

EFFECTIVE

DATE

REVISION

NUMBER DESCRIPTION

10/15/2009 00 New technical information bulletin for internal dosimetry coworker 

data for Los Alamos National Laboratory. Incorporates formal internal 

and NIOSH review comments. Analysis of plutonium-239 and 

cesium-137 lung counts updated and new guidance added for type 

Super S plutonium-239. Training required: As determined by the 

Objective Manager. Initiated by Matthew Arno.

09/01/2020 01 Revision initiated to include the intake rates for type SS plutonium. 

Incorporates formal internal and NIOSH review comments. 

Constitutes a total rewrite of the document. Training required: As 

determined by the Objective Manager. Initiated by Matthew G. Arno.
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 3 of 113

TABLE OF CONTENTS

SECTION TITLE PAGE

Acronyms and Abbreviations ............................................................................................................. 12

1.0 Introduction ............................................................................................................................ 13

2.0 Purpose ................................................................................................................................. 13

3.0 Data Overview ....................................................................................................................... 13

3.1 Bioassay Data Selection............................................................................................. 14

3.2 Analysis...................................................................................................................... 14

3.3 Tritium ........................................................................................................................ 14

3.4 Plutonium-238 ............................................................................................................ 15

3.5 Plutonium-239 ............................................................................................................ 16

3.5.1 Plutonium-239 In Vitro Data ......................................................................... 16

3.5.2 Plutonium-239 In Vivo Data.......................................................................... 18

3.6 Polonium-210 ............................................................................................................. 18

3.7 Uranium...................................................................................................................... 19

3.8 Cesium-137................................................................................................................ 19

4.0 Intake Modeling...................................................................................................................... 20

4.1 Assumptions............................................................................................................... 20

4.2 Bioassay Fitting .......................................................................................................... 20

4.3 Material Types............................................................................................................ 20

4.3.1 Tritium.......................................................................................................... 21

4.3.2 Plutonium-238.............................................................................................. 21

4.3.3 Plutonium-239.............................................................................................. 22

4.3.4 Polonium...................................................................................................... 22

4.3.5 Uranium ....................................................................................................... 23

4.3.6 Cesium-137.................................................................................................. 23

5.0 Assigning Intakes and Doses ................................................................................................. 24

5.1 Intake Rate Summary................................................................................................. 24

5.2 Tritium ........................................................................................................................ 24

5.3 Plutonium-238 ............................................................................................................ 25

5.4 Plutonium-239 ............................................................................................................ 25

5.5 Polonium .................................................................................................................... 26

5.6 Uranium...................................................................................................................... 27

5.7 Cesium-137................................................................................................................ 27

6.0 Attributions and Annotations .................................................................................................. 27

References ........................................................................................................................................ 28

ATTACHMENT A CO-EXPOSURE DATA TABLES .................................................................... 29

ATTACHMENT B CO-EXPOSURE DATA FIGURES .................................................................. 34
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 4 of 113

LIST OF TABLES

TABLE TITLE PAGE

3-1 High bioassay readings for 238Pu............................................................................................ 15

3-2 High bioassay readings for 239Pu............................................................................................ 17

5-1 Tritium annual doses and GSDs............................................................................................. 24

5-2 Plutonium-238 type M and S intake rates............................................................................... 25

5-3 Plutonium-239 type M intake rates ......................................................................................... 25

5-4 Plutonium-239 type S intake rates.......................................................................................... 26

5-5 Plutonium-239 type SS intake rates ....................................................................................... 26

5-6 Polonium type F and M intake rates ....................................................................................... 26

5-7 August 1, 1955, incident type F and M polonium intakes........................................................ 27

5-8 Uranium types F, M, and S intake rates ................................................................................. 27

5-9 Type F 137Cs intake rates ....................................................................................................... 27

A-1 Statistical summary of 238Pu urinary excretion rates, 1968 to 2008......................................... 30

A-2 Statistical summary of 239Pu urinary excretion rates, 1945 to 2008......................................... 31

A-3 Statistical summary of 239Pu lung burdens, 1969 to 1979 ....................................................... 31

A-4 Statistical summary of polonium urinary excretion rates, 1947 to 1956 .................................. 32

A-5 Statistical summary of uranium urinary excretion rates, 1950 to 2008.................................... 33

A-6 Statistical summary of cesium whole-body counts, 1970 to 1993........................................... 33

B-1 Summary of 238Pu type M intake rates and dates ................................................................... 50

B-2 Summary of 238Pu type S intake rates and dates.................................................................... 58

B-3 Summary of 239Pu type M intake rates and dates ................................................................... 68

B-4 Summary of 239Pu type S urinalysis-based intake rates and dates ......................................... 78

B-5 Summary of 239Pu type S lung burden-based intake rates and dates ..................................... 83

B-6 Summary of 239Pu type SS urinalysis-based intake rates and dates ....................................... 90

B-7 Summary of 239Pu type SS lung burden-based intake rates and dates ................................... 94

B-8 Summary of polonium type F intake rates and dates.............................................................. 94

B-9 Summary of polonium type M intake rates and dates ............................................................. 95

B-10 Summary of polonium acute intakes type F and M............................................................... 102

B-11 Summary of uranium type F intake rates and dates ............................................................. 103

B-12 Summary of uranium type M intake rates and dates............................................................. 104

B-13 Summary of uranium type S intake rates and dates ............................................................. 112

B-14 Summary of type F 137Cs intake rates and dates .................................................................. 113

LIST OF FIGURES

FIGURE TITLE PAGE

B-1 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1968 to 1971, 50th percentile, type M ....................... 42

B-2 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1972, 50th percentile, type M.................................... 42

B-3 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1973 to 1974, 50th percentile, type M ....................... 43

B-4 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1975 to 1977, 50th percentile, type M ....................... 43

B-5 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1978 to 1981, 50th percentile, type M ....................... 44

B-6 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1982 to 1988, 50th percentile, type M ....................... 44
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 5 of 113

B-7 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1989 to 1993, 50th percentile, type M ....................... 45

B-8 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1994 to 2008, 50th percentile, type M ....................... 45

B-9 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1968 to 1971, 84th percentile, type M ....................... 46

B-10 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1972, 84th percentile, type M.................................... 46

B-11 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1973 to 1974, 84th percentile, type M ....................... 47

B-12 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1975 to 1981, 84th percentile, type M ....................... 47

B-13 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1982 to 1988, 84th percentile, type M ....................... 48

B-14 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1989 to 1993, 84th percentile, type M ....................... 48

B-15 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1994 to 2008, 84th percentile, type M ....................... 49

B-16 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots) from all intakes, 50th percentile, type M ..................... 49

B-17 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots) from all intakes, 84th percentile, type M ..................... 50

B-18 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1968 to 1971, 50th percentile, type S........................ 50

B-19 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1972, 50th percentile, type S .................................... 51

B-20 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1973 to 1974, 50th percentile, type S........................ 51

B-21 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1975 to 1981, 50th percentile, type S........................ 52

B-22 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1982 to 1988, 50th percentile, type S........................ 52

B-23 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1989 to 1993, 50th percentile, type S........................ 53

B-24 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1994 to 2008, 50th percentile, type S........................ 53

B-25 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1968 to 1971, 84th percentile, type S........................ 54

B-26 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1972, 84th percentile, type S .................................... 54

B-27 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1973 to 1974, 84th percentile, type S........................ 55

B-28 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1975 to 1981, 84th percentile, type S........................ 55

B-29 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1982 to 1988, 84th percentile, type S........................ 56

B-30 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1989 to 1993, 84th percentile, type S........................ 56

B-31 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1994 to 2008, 84th percentile, type S........................ 57

B-32 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots) from all intakes, 50th percentile, type S...................... 57
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 6 of 113

B-33 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots) from all intakes, 84th percentile, type S...................... 58

B-34 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots), 1944 to 1945, 50th percentile, type M ....................... 58

B-35 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots), 1946, 50th percentile, type M.................................... 59

B-36 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots), 1947, 50th percentile, type M.................................... 59

B-37 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots), 1954 to 1956, 50th percentile, type M ....................... 60

B-38 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots), 1957 to 1966, 50th percentile, type M ....................... 60

B-39 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots), 1967 to 1972, 50th percentile, type M ....................... 61

B-40 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots), 1973 to 1975, 50th percentile, type M ....................... 61

B-41 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots), 1976 to 1993, 50th percentile, type M ....................... 62

B-42 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots), 1994 to 2008, 50th percentile, type M ....................... 62

B-43 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots), 1944 to 1945, 84th percentile, type M ....................... 63

B-44 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots), 1946, 84th percentile, type M.................................... 63

B-45 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots), 1947 to 1954, 84th percentile, type M ....................... 64

B-46 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots), 1955 to 1956, 84th percentile, type M ....................... 64

B-47 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots), 1957 to 1966, 84th percentile, type M ....................... 65

B-48 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots), 1967 to 1972, 84th percentile, type M ....................... 65

B-49 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots), 1973 to 1975, 84th percentile, type M ....................... 66

B-50 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots), 1976 to 1993, 84th percentile, type M ....................... 66

B-51 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots), 1994 to 2008, 84th percentile, type M ....................... 67

B-52 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots) from all intakes, 50th percentile, type M ..................... 67

B-53 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots) from all intakes, 84th percentile, type M..................... 68

B-54 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1944 to 1945, 50th percentile, type S...... 68

B-55 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1946, 50th percentile, type S................... 69

B-56 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1947 to 1953, 50th percentile, type S...... 69

B-57 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1954 to 1956, 50th percentile, type S...... 70

B-58 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1957 to 1966, 50th percentile, type S...... 70
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 7 of 113

B-59 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1967 to 1972, 50th percentile, type S...... 71

B-60 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1973 to 1975, 50th percentile, type S...... 71

B-61 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1976 to 1993, 50th percentile, type S...... 72

B-62 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1994 to 2008, 50th percentile, type S...... 72

B-63 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1944 to 1945, 84th percentile, type S...... 73

B-64 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1946, 84th percentile, type S................... 73

B-65 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1947 to 1954, 84th percentile, type S...... 74

B-66 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1955 to 1956, 84th percentile, type S...... 74

B-67 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1957 to 1966, 84th percentile, type S...... 75

B-68 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1967 to 1972, 84th percentile, type S...... 75

B-69 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1973 to 1975, 84th percentile, type S...... 76

B-70 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1976 to 1993, 84th percentile, type S...... 76

B-71 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1994 to 2008, 84th percentile, type S...... 77

B-72 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots) from all intakes, 50th percentile, 

type S.....................................................................................................................................77

B-73 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots) from all intakes, 84th percentile, 

type S.....................................................................................................................................78

B-74 Predicted 239Pu lung burden bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1969 to 1971, 50th percentile, type S...... 78

B-75 Predicted 239Pu lung burden bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1972 to 1974, 50th percentile, type S...... 79

B-76 Predicted 239Pu lung burden bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1975, 50th percentile, type S................... 79

B-77 Predicted 239Pu lung burden bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1976 to 1977, 50th percentile, type S...... 80

B-78 Predicted 239Pu lung burden bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1978 to 1979, 50th percentile, type S...... 80

B-79 Predicted 239Pu lung burden bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1969 to 1971, 84th percentile, type S...... 81

B-80 Predicted 239Pu lung burden bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1972 to 1974, 84th percentile, type S...... 81

B-81 Predicted 239Pu lung burden bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1975, 84th percentile, type S................... 82

B-82 Predicted 239Pu lung burden bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1976 to 1977, 84th percentile, type S...... 82

B-83 Predicted 239Pu lung burden bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1978 to 1979, 84th percentile, type S...... 83
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 8 of 113

B-84 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1944 to 1945, 50th percentile, type 

SS..........................................................................................................................................83

B-85 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1946, 50th percentile, type SS ................ 84

B-86 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1947 to 1953, 50th percentile, type 

SS..........................................................................................................................................84

B-87 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1954 to 1956, 50th percentile, type 

SS..........................................................................................................................................84

B-88 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1957 to 1966, 50th percentile, type 

SS..........................................................................................................................................85

B-89 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1967 to 1972, 50th percentile, type 

SS..........................................................................................................................................85

B-90 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1973 to 1975, 50th percentile, type 

SS..........................................................................................................................................85

B-91 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1976 to 1993, 50th percentile, type 

SS..........................................................................................................................................86

B-92 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1994 to 2008, 50th percentile, type 

SS..........................................................................................................................................86

B-93 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1944 to 1945, 84th percentile, type 

SS..........................................................................................................................................86

B-94 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1946, 84th percentile, type SS ................ 87

B-95 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1947 to 1954, 84th percentile, type 

SS..........................................................................................................................................87

B-96 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1955 to 1956, 84th percentile, type 

SS..........................................................................................................................................87

B-97 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1957 to 1966, 84th percentile, type 

SS..........................................................................................................................................88

B-98 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1967 to 1972, 84th percentile, type 

SS..........................................................................................................................................88

B-99 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1973 to 1975, 84th percentile, type 

SS..........................................................................................................................................88

B-100 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1976 to 1993, 84th percentile, type 

SS..........................................................................................................................................89

B-101 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1994 to 2008, 84th percentile, type 

SS..........................................................................................................................................89
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 9 of 113

B-102 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots) from all intakes, 50th percentile, type 

SS..........................................................................................................................................89

B-103 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots) from all intakes, 84th percentile, type 

SS..........................................................................................................................................90

B-104 Predicted 239Pu lung burden bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1969 to 1971, 50th percentile, type 

SS..........................................................................................................................................90

B-105 Predicted 239Pu lung burden bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1972 to 1974, 50th percentile, type 

SS..........................................................................................................................................91

B-106 Predicted 239Pu lung burden bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1975, 50th percentile, type SS ................ 91

B-107 Predicted 239Pu lung burden bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1976 to 1977, 50th percentile, type 

SS..........................................................................................................................................91

B-108 Predicted 239Pu lung burden bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1978 to 1979, 50th percentile, type 

SS..........................................................................................................................................92

B-109 Predicted 239Pu lung burden bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1969 to 1971, 84th percentile, type 

SS..........................................................................................................................................92

B-110 Predicted 239Pu lung burden bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1972 to 1974, 84th percentile, type 

SS..........................................................................................................................................92

B-111 Predicted 239Pu lung burden bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1975, 84th percentile, type SS ................ 93

B-112 Predicted 239Pu lung burden bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1976 to 1977, 84th percentile, type 

SS..........................................................................................................................................93

B-113 Predicted 239Pu lung burden bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1978 to 1979, 84th percentile, type 

SS..........................................................................................................................................93

B-114 Predicted polonium bioassay results calculated using IMBA-derived polonium intake 

rates (line) compared with bioassay results (dots) from all intakes, 50th percentile, type F .... 94

B-115 Predicted polonium bioassay results calculated using IMBA-derived polonium intake 

rates (line) compared with bioassay results (dots) from all intakes, 84th percentile, type F .... 94

B-116 Predicted polonium bioassay results calculated using IMBA-derived polonium intake 

rates (line) compared with bioassay results (dots) from all intakes, 50th percentile, type 

M............................................................................................................................................95

B-117 Predicted polonium bioassay results calculated using IMBA-derived polonium intake 

rates (line) compared with bioassay results (dots) from all intakes, 84th percentile, type 

M............................................................................................................................................95

B-118 Predicted polonium acute intake bioassay fit calculated using an IMBA-derived polonium 

intake rate (line) compared with bioassay results (dots) for individual “A,” type F................... 96

B-119 Predicted polonium acute intake bioassay fit calculated using an IMBA-derived polonium 

intake rate (line) compared with bioassay results (dots) for individual “B,” type F................... 96

B-120 Predicted polonium acute intake bioassay fit calculated using an IMBA-derived polonium 

intake rate (line) compared with bioassay results (dots) for individual “C,” type F................... 97

B-121 Predicted polonium acute intake bioassay fit calculated using an IMBA-derived polonium 

intake rate (line) compared with bioassay results (dots) for individual “D,” type F................... 97
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 10 of 113

B-122 Predicted polonium acute intake bioassay fit calculated using an IMBA-derived polonium 

intake rate (line) compared with bioassay results (dots) for individual “E,” type F................... 98

B-123 Predicted polonium acute intake bioassay fit calculated using an IMBA-derived polonium 

intake rate (line) compared with bioassay results (dots) for individual “F,” type F ................... 98

B-124 Predicted polonium acute intake bioassay fit calculated using an IMBA-derived polonium 

intake rate (line) compared with bioassay results (dots) for individual “G,” type F .................. 99

B-125 Predicted polonium acute intake bioassay fit calculated using an IMBA-derived polonium

intake rate (line) compared with bioassay results (dots) for individual “A,” type M .................. 99

B-126 Predicted polonium acute intake bioassay fit calculated using an IMBA-derived polonium 

intake rate (line) compared with bioassay results (dots) for individual “B,” type M ................ 100

B-127 Predicted polonium acute intake bioassay fit calculated using an IMBA-derived polonium 

intake rate (line) compared with bioassay results (dots) for individual “C,” type M................ 100

B-128 Predicted polonium acute intake bioassay fit calculated using an IMBA-derived polonium 

intake rate (line) compared with bioassay results (dots) for individual “D,” type M................ 101

B-129 Predicted polonium acute intake bioassay fit calculated using an IMBA-derived polonium 

intake rate (line) compared with bioassay results (dots) for individual “E,” type M ................ 101

B-130 Predicted polonium acute intake bioassay fit calculated using an IMBA-derived polonium 

intake rate (line) compared with bioassay results (dots) for individual “F,” type M ................ 102

B-131 Predicted polonium acute intake bioassay fit calculated using an IMBA-derived polonium 

intake rate (line) compared with bioassay results (dots) for individual “G,” type M................ 102

B-132 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots) from all intakes, 50th percentile, type F........... 103

B-133 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots) from all intakes, 84th percentile, type F........... 103

B-134 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots) from all intakes, 50th percentile, type M .......... 104

B-135 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots) from all intakes, 84th percentile, type M .......... 104

B-136 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots), 1950 to 1955, 50th percentile, type S............. 105

B-137 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots), 1956 to 1957, 50th percentile, type S............. 105

B-138 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots), 1958 to 1965, 50th percentile, type S............. 106

B-139 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots), 1966 to 1973, 50th percentile, type S............. 106

B-140 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots), 1974 to 1982, 50th percentile, type S............. 107

B-141 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots), 1983 to 1989, 50th percentile, type S............. 107

B-142 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots), 1990 to 2008, 50th percentile, type S............. 108

B-143 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots), 1950 to 1955, 84th percentile, type S............. 108

B-144 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots), 1956 and 1957, 84th percentile, type S.......... 109

B-145 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots), 1958 to 1965, 84th percentile, type S............. 109

B-146 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots), 1966 to 1973, 84th percentile, type S............. 110

B-147 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots), 1974 to 1982, 84th percentile, type S............. 110
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 11 of 113

B-148 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots), 1983 to 1989, 84th percentile, type S............. 111

B-149 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots), 1990 to 2008, 84th percentile, type S............. 111

B-150 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots), all intake periods, 50th percentile, type S....... 112

B-151 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots), all intake periods, 84th percentile, type S....... 112

B-152 Predicted cesium bioassay results calculated using IMBA-derived cesium intake rates 

(line) compared with bioassay results (dots) from all intakes, 50th percentile, type F........... 113

B-153 Predicted cesium bioassay results calculated using IMBA-derived cesium intake rates 

(line) compared with bioassay results (dots) from all intakes, 84th percentile, type F........... 113
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 12 of 113

ACRONYMS AND ABBREVIATIONS

AWE atomic weapons employer

d day

DOE U.S. Department of Energy

DTPA diethylene triamine pentaacetic acid

F fast (absorption type)

GM geometric mean

GSD geometric standard deviation

hr hour

ICRP International Commission on Radiological Protection

IDOT Internal Dosimetry Tool

IMBA Integrated Modules for Bioassay Analysis

L liter

LANL Los Alamos National Laboratory

m meter

M moderate (absorption type)

MDA minimum detectable activity

mL milliliter

mrem millirem

nCi nanocurie

NIOSH National Institute for Occupational Safety and Health

ORAU Oak Ridge Associated Universities

pCi picocurie

RAS radiometric alpha spectrometry

S slow (absorption type)

SEC Special Exposure Cohort

SRDB Ref ID Site Research Database Reference Identification (number)

SS super slow (absorption type)

TIB technical information bulletin

TIMS thermal ionization mass spectrometry

USC United States Code

μCi microcurie

μg microgram

μm micrometer
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 13 of 113

1.0 INTRODUCTION

Technical information bulletins (TIBs) are not official determinations made by the National Institute for 

Occupational Safety and Health (NIOSH) but are rather general working documents that provide 

historical background information and guidance to assist in the preparation of dose reconstructions at 

particular sites or categories of sites. They will be revised in the event additional relevant information 

is obtained about the affected site(s), such as changing scientific understanding of operations, 

processes, or procedures involving radioactive materials. TIBs may be used to assist NIOSH staff in 

the completion of individual dose reconstructions.

In this document the word “facility” is used to refer to an area, building, or group of buildings that 

served a specific purpose at a U.S. Department of Energy (DOE) or Atomic Weapons Employer 

(AWE) facility. It does not mean, nor should it be equated to, an “AWE facility” or a “DOE facility.” The 

terms AWE and DOE facility are defined in 42 United States Code (USC) 7384l(5) and (12) of the 

Energy Employees Occupational Illness Compensation Program Act of 2000, respectively.

ORAUT-OTIB-0019, Analysis of Coworker Bioassay Data for Internal Dose Assignment, describes the 

general process used to analyze bioassay data for the assignment of doses to individuals based on 

co-exposure results [ORAUT 2005]. ORAUT-PLAN-0014, Coworker Data Exposure Profile 

Development, describes the approach and processes to develop reasonable exposure profiles based 

on available dosimetric information for workers at DOE sites [ORAUT 2004a].

Bioassay results were obtained directly from the Los Alamos National Laboratory (LANL) In-Vivo 

Measurements Laboratory and from the LANL Bioassay Repository for in vitro bioassay results. The 

combined databases used here contain more than half a million bioassay records from LANL and 

include measurements for 238Pu, plutonium, tritium, polonium, and cesium for 1945 to 2008.

The database results were labeled with units that varied among the radionuclides, analysis 

techniques, and measurement periods. These units usually were disintegrations per minute, counts 

per minute, or picocuries per 24 hours or per liter. The specific units for each radionuclide are 

provided in the appropriate sections of this document.

A statistical analysis of the data was performed according to ORAUT-OTIB-0019 and ORAUT-PROC0095, Generating Summary Statistics for Coworker Bioassay Data [ORAUT 2005, 2006]. The results 

were entered in the Integrated Modules for Bioassay Analysis (IMBA) to obtain intake rates for the 

assignment of dose distributions.

2.0 PURPOSE

Some employees at DOE sites were not monitored for potential intakes of radioactive material, or the 

records of such monitoring are incomplete or unavailable. In such cases, co-exposure data from other 

monitored workers can be used to assign an internal dose to address potential intakes of radioactive 

material. The purpose of this TIB is to provide monitored co-exposure information for calculating and 

assigning occupational internal doses to employees at LANL for whom no or insufficient monitoring 

records exist.

3.0 DATA OVERVIEW

This section provides information on the general selection characteristics of the data and the methods 

of analysis. More detailed radionuclide-specific information is provided in Section 4.0.
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 14 of 113

3.1 BIOASSAY DATA SELECTION

Urinalysis data for 238

Pu, plutonium, polonium, uranium, and tritium from 1945 to 2004 were extracted 

from a database named “LANL CO-Worker Data – Rev 1.mdb” [“co-exposure database”; ORAUT 

2009a]. There are more than 400,000 records in the urinalysis database. Six measurements for 239Pu 

in 1944 were not used because the low number of measurements does not permit reliable statistical 

analysis. The same data for 2005 through 2008 was extracted from a database named 

“LANL_invitro_dataset_feb2009.mdb” [“in vitro database”; ORAUT 2009b], which contains more than 

55,000 additional urinalysis results. The units used were dependent on both the analyte and the era. 

The specific units used are discussed in more detail below in the discussion of each radionuclide.

In vivo data from 1965 to 2004 were extracted from a database named 2007_10_08-

“LANL_IN_VIVO_DATA-Access2003.mdb” [“in vivo database”; ORAUT 2007]. There are 

approximately 100,000 records in this database. Most of the records are for chest or whole-body 

counts, although a few counts of specific organs or body regions (hand, skull, etc.) are included. Only 

the chest and whole-body counts were used. Bioassay data were available for in vivo measurements 

of 238Pu, 239Pu, 241Am, and 137Cs. Beyond these four nuclides, very limited data were available, 

primarily for the late 1980s when the use of high-resolution germanium detectors became more 

widespread, which allowed identification of a wide selection of other radionuclides. However, 

insufficient data were available to perform any analysis for these other radionuclides. Even for the four 

primary radionuclides, sufficient non-zero data for analysis were available only for 239Pu and 137Cs.

3.2 ANALYSIS

Bioassay data were analyzed by quarter, year, or multiyear span dependent on the amount of data 

available for each radionuclide during a given period and the expected biokinetics of each 

radionuclide. A lognormal distribution was assumed. After log-transforming the data, the 50th and 

84th percentiles were determined for each period using the method in ORAUT-OTIB-0019 [ORAUT 

2005]. A large fraction of the data for every radionuclide was entered as zero bioassay results. These 

zeros were retained in the analysis to rank the results. The acute intake of polonium in 1955 was 

addressed differently as discussed below in the sections regarding polonium.

3.3 TRITIUM

Tritium urine bioassay data were extracted from the co-exposure database [ORAUT 2009a]. The 

co_worker_data table in this database was queried to identify all records with a nuclide type of “H-3”

and collection dates ranging from the earliest recorded through the end of 2004. The coll_date, 

z_number, and activity fields were extracted and exported to a spreadsheet. All activity results were in 

microcuries per liter. No other codes or fields with useful information were identified.

For the period from the start of data (June 23, 1950) through approximately 1991, no records had 

fields that contained information that would permit the sorting or exclusion of any data points. Later 

data (post-1991) identified samples as routine or special, but all pre-1989 data were identified as 

historical spot samples. All data were used. A total of 72,153 distinct records were identified.

Visual examination of the data indicates that almost all of the high bioassay values are clearly the 

result of acute intakes. Involved employees were regularly monitored while the tritium was excreted, 

which resulted in well-defined decaying exponential excretion curves. No attempt was made to 

exclude the bioassay data resulting from these acute intakes.

The minimum detectable activity (MDA) for the entire period was 1 μCi/L until late 1987, when the 

MDA decreased to 0.1 μCi/L. Before 1991, MDAs were reported in the database separately from the 

analytical result. Analytical results <MDA were recorded as zero, except for December 1968 through 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 15 of 113

January 1971, when the actual result was recorded. Starting in 1991, the actual result, regardless of 

whether it was above or below the MDA, was reported and the MDA was not reported separately. 

Activities recorded in site records as less than the MDA were input as one-half of the MDA for this 

analysis. 

For 2005 through 2008, tritium urine bioassay data were extracted from the LANL IN VITRO DATA 

FEB 2009 table in the in vitro database [“in vitro database”; ORAUT 2009b]. All records with a nuclide 

type of “H-3” and collection dates ranging from 2005 through 2008 inclusive were identified. The ZNO, 

COLLECTED_DATE, and ACTIVITY fields were extracted and exported to a spreadsheet. All activity 

results were in microcuries per liter. No other codes or fields with useful information were identified. A 

total of 5,186 distinct records were identified. The actual result, regardless of whether it was above or 

below the MDA, was reported along with the MDA.

3.4 PLUTONIUM-238

The co_worker_data table in the co-exposure database [ORAUT 2009a] was queried to identify all 

records with a nuclide type of “PU-238” and collection dates that ranged from the beginning of 1968 

through the end of 2004. Predominantly pure 238Pu was not encountered at LANL before 1968 

[ORAUT 2013]. The coll_date, z_number, and activity fields were extracted and exported to a 

spreadsheet. All activity results were in units of picocuries per 24 hours. For the period from the start 

of data (1968) through the end of 1990, all the data had the same information available in the 

database with no fields that contained information that would permit the sorting or exclusion of any 

data points. Later data (post-1991) identified samples as routine or special, but all pre-1991 data were 

identified as simply historical samples. All data were used. 

It appears that values less than the MDA were reported beginning in 1971 with negative results 

reported as zero. Negative results were reported beginning in 1973 except for two results in 1971. All 

activity values, including zero, less than zero, and less-than MDA, were used without modification for 

all years. 

The statistical analysis was performed on an annual basis using a total of 77,739 distinct records. 

Table A-1 in Attachment A lists the statistical analysis results for 238Pu.

Examination of the reported activities revealed that a relatively small number of individuals accounted 

for the majority of the highest bioassay results. These results tended to skew the curve fit. The 

bioassay results for these individuals were filtered out for the indicated years to eliminate this skew. 

Table 3-1 lists the individuals whose results were filtered out and for which years. Additional detail, 

with personally identifiable information removed, for filtering out these individuals is provided below.

Table 3-1. High bioassay readings for 

238Pu. 

Individual Years filtered out

1 1972 through 1988

2 1972 through 1988

3 1972 through 1988

4 1977 through 1988

5 1981 through 1988

Individuals 1 through 3

These individuals were involved in the Wing-9 incident in 1971, which has been the subject of multiple 

studies [Hickman et al. 1995; James et al 2003]. Their bioassay data is well studied and associated 

with a known incident. Their data was removed for 1972 through 1988.
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 16 of 113

Individual 4

This individual had an acute intake on February 10, 1977, and was bioassayed 96 times during 1977 

and treated with diethylene triamine pentaacetic acid (DTPA) [Various 1976–1980]. The bioassay 

measurements exhibit a clear exponential decay, and the initial data were extreme outliers and 

skewed the fit. All data for this individual for 1977 through 1988 were removed. The same pattern was 

seen in this individual’s 239Pu bioassay measurements.

Individual 5

This individual had an acute intake in mid-April 1981 [Inkret and Miller 1995]. He was sampled 

numerous times, and the bioassay data exhibits an exponential decay trend. All data for this individual 

for 1981 through 1988 were removed. This individual also had high 239Pu bioassay measurements 

starting at the same time.

For 2005 through 2008, the LANL IN VITRO DATA FEB 2009 table in the in vitro database [ORAUT 

2009a] was queried to identify all records with a nuclide type of “PU-238” and collection dates that 

ranged from the beginning of 2005 through the end of 2008. The ZNO, COLLECTED_DATE, 

SAMPLE_ID, ACTIVITY_PS and ACTIVITY fields were extracted and exported to a spreadsheet. For 

a given SAMPLE_ID, the ACTIVITY_PS field was used as the sample activity unless it was blank, in 

which case the value in the ACTIVITY field was used as the result. All samples were 24-hour or 

simulated 24-hour samples and were in units of picocuries per sample or picocuries per 24 hours. 

Therefore, all results were treated as picocuries per day. All data were used.

3.5 PLUTONIUM-239

3.5.1 Plutonium-239 In Vitro Data

The co_worker_data table in the co-exposure database [ORAUT 2009a] was queried to identify all 

urinalysis records with a nuclide type of “PU-239” and collection dates that ranged from the beginning 

of 1945 through the end of 2004. The coll_date, z_number, and activity fields were extracted and 

exported to a spreadsheet. All activity results were in units of picocuries per 24 hours. For the period 

from the start of data (1944) through approximately 1991, all the data had the same information 

available in the database with no fields that contained information that would permit the sorting or 

exclusion of any data points. Later data (post-1991) identified samples as routine or special, but all 

pre-1989 data were identified as simply historical samples. All data were used.

Values less than the MDA and negative results were reported as such from 1945 through 1957 and 

from 1971 onward. For 1958 through 1970, values less than zero were reported as zero. All activity 

values, including zero, less than zero, and above-MDA, were used without modification for all years. 

Before 1967, plutonium urinalysis measured gross plutonium alpha activity rather than 239/240Pu 

activity. However, the pre-1967 data has been treated as measuring the 239/240Pu count rate, which 

overestimates the actual 239/240Pu activity by 10% to 12% for weapons-grade plutonium depending on 

the fuel age. The statistical analysis was performed on an annual basis using 85,752 distinct records. 

Table A-2 in Attachment A lists the statistical analysis results for in vitro 239Pu.

Examination of the reported activities revealed that, for a few years, a few individuals were 

responsible for the vast majority of the highest bioassay results. These results tended to skew the 

curve fit. The bioassay results for these individuals were filtered out for the specific year to eliminate 

this skew. Table 3-2 lists the individuals whose results were filtered out and for which years. The 

justification for filtering out these individuals is the same as given for 238Pu above.

For 2005 through 2008, the LANL IN VITRO DATA FEB 2009 table in the in vitro database [ORAUT 

2009a] was queried to identify all records with a nuclide type of “PU-239,” “PU-240,” or “PU-239+PU240” and collection dates that ranged from the beginning of 2005 through the end of 2008. The ZNO, 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 17 of 113

COLLECTED_DATE, SAMPLE_ID, ANALYSIS_TYPE, ACTIVITY_PS and ACTIVITY fields were 

extracted and exported to a spreadsheet. All samples were 24-hour or simulated 24-hour samples 

and were in units of picocuries per sample or picocuries per 24 hours. Therefore, all results were 

treated as picocuries per day. 

Table 3-2. High bioassay readings for 239Pu. 

Individual Years filtered out

4 1977 through 1988

5 1981 through 1988

Plutonium-239/240 results were obtained by both radiometric alpha spectrometry (RAS) and thermal 

ionization mass spectrometry (TIMS). The TIMS results report separate concentrations for 239Pu and 

240Pu. RAS results do not distinguish between 239Pu and 240Pu because the alpha particle energies for 

these two radionuclides are very similar and report the combined activity as PU-239. The TIMS results 

have a lower limit of detection and are generally more reliable. For this study, the combined 239/240Pu

activity is the desired quantity. A single SAMPLE_ID in the database might have as many as eight

records associated with it. To determine the single quantity to use for this study, the following priority 

order was used:

For a given SAMPLE_ID, use the record(s) highest in the following priority list:

1. NUCLIDE field = “PU-239+PU-240,” ANALYSIS_TYPE = “TIMS,” recorded value in the 

ACTIVITY_PS field. 

2. NUCLIDE field = “PU-239+PU-240,” ANALYSIS_TYPE = “TIMS,” ACTIVITY_PS field blank, 

with a recorded value in the ACTIVITY field. 

3. Sum the ACTIVITY_PS fields of:

a. NUCLIDE field = “PU-239+PU-240,” ANALYSIS_TYPE = “TIMS,” recorded value in the 

ACTIVITY_PS field, and

b. NUCLIDE field = “PU-239+PU-240,” ANALYSIS_TYPE = “TIMS,” recorded value in the 

ACTIVITY_PS field.

4. Sum the ACTIVITY fields of:

a. NUCLIDE field = “PU-239+PU-240,” ANALYSIS_TYPE = “TIMS,” ACTIVITY_PS field 

blank, recorded value in the ACTIVITY field, and

b. NUCLIDE field = “PU-239+PU-240,” ANALYSIS_TYPE = “TIMS,” ACTIVITY_PS field 

blank, recorded value in the ACTIVITY field. 

5. NUCLIDE field = “PU-239,” ANALYSIS_TYPE = “RAS,” recorded value in the ACTIVITY_PS 

field.

6. NUCLIDE field = “PU-239,” ANALYSIS_TYPE = “RAS,” ACTIVITY_PS field blank, recorded 

value in the ACTIVITY field. 

A single value for each SAMPLE_ID was used. All SAMPLE_IDs with reported 239Pu and/or 240Pu

results were used. In 2007, one individual had the 67 largest results. All of this person’s bioassay data

in 2007 was excluded from the analysis.
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 18 of 113

3.5.2 Plutonium-239 In Vivo Data

The TBL_NIOSH_REPORT_2007_V2 table in the in vivo database [ORAUT 2007] was queried to 

identify all lung count records with a nuclide type of “Pu-239,” organ type of “Chest,” count reason 

other than “new hire,” “rehire,” or “baseline,” and collection dates ranging from the beginning of 1969 

through the end of 2004. The count_date, zno, and abundance_nCi fields were extracted and 

exported to a spreadsheet. The zno field was used as the employee identifier, and the 

abundance_nCi field was used as the value of the chest count.

Records with no abundance value were entered with an abundance of zero based on the assumption 

that the result was less than the MDA and the fact that the recorded MDAs were much higher than the 

typical recorded positive values. Only 1969 through 1979 were analyzed because there were few 

positive results after 1979. Table A-3 in Attachment A lists the statistical analysis results for in vivo 

239Pu.

3.6 POLONIUM-210

The co_worker_data table in the co-exposure database [ORAUT 2009a] database was queried to 

identify all records with a nuclide type of “Po” and collection dates that ranged from the beginning of 

1947 through the end of 2004. The coll_date, z_number, and activity fields were extracted and 

exported to a spreadsheet. The activity results were reported in units of picocuries per liter or counts 

per minute per liter. Results in counts per minute were converted to disintegrations per minute using a 

detector efficiency of 50% (based on the assumption that a 2-π detector was used in the absence of 

any other information) and a recovery fraction of 10%. The results in disintegrations per minute were 

then converted to picocuries for consistency with the other data. Results in picocuries per liter were 

adjusted assuming a recovery fraction of 10% rather than 100% [ORAUT 2017]. All the data had the 

same information available in the database with no fields that contained information that would permit 

the sorting or exclusion of any data points. Therefore, all data were used.

Examination of the data indicated several anomalies. Several individuals had acute intakes in January 

1953. Because more than one individual was involved (even though a limited number), these data 

were left in the dataset for the entire year. In August 1954, one employee had an acute intake that 

resulted in all of the highest 20% of bioassay results for the year. All bioassay results for this 

employee for the third and fourth quarters of 1954 were excluded from the analysis.

Another acute intake involving a large number of individuals occurred in late July or early August 

1955. To separate the urinalysis results due to this acute intake, urinalysis results for seven 

employees were excluded from the fits for the last two quarters of 1955. Although these seven 

individuals were not the only ones involved in the incident, these seven had the majority of the highest 

readings. The bioassay data for these seven individuals as a result of this incident have been 

analyzed separately as an acute intake. Dose reconstruction for individuals who were involved in this 

incident and who do not have relevant bioassay data should also be assigned this intake. This applies 

only to individuals for whom there is evidence or reason to believe that they were involved in this 

incident. An incident date of August 1, 1955, was chosen as the best fit to the available data.

All activity values, including zero, less than zero, and less-than MDA, were used without modification 

for all years. The normal statistical analysis was performed on a quarterly basis. For the seven 

identified individuals involved in the incident, the bioassay data for each individual was fit separately 

to determine the intake of material that occurred in the incident. Table A-4 in Attachment A lists the 

statistical analysis results for 210Po. A total of 5,121 distinct records were used for the quarterly and 

incident analyses.
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 19 of 113

3.7 URANIUM

The co_worker_data table in the co-exposure database [ORAUT 2009a] was queried to identify all

records with a nuclide type of “U-234,” “U-235,” or “U-238” and collection dates ranging from 1950 

through the end of 2004. The coll_date, z_number, activity, and MDA fields were extracted and 

exported to a spreadsheet. All activity results were in units of picocuries per 24 hours. For the period 

from the start of data (1950) through approximately 1991, all the data had the same information 

available in the database with no fields that contained information that would permit the sorting or 

exclusion of any data points. Later data (post-1991) identified samples as routine or special, but all 

pre-1989 data were identified as historical spot samples. All data were used.

Before July 1991, the bioassay records identified the results as being specific for either 238U or 235U. 

However, both techniques truly measured the same quantity but reported the results in different units. 

A single measurement technique was used during any given time frame [see Table 5-13 in ORAUT 

2013] for analysis of uranium in urine before 1991. The analytical results were interpreted based on 

the materials to which an individual was presumed to have been exposed. Therefore, the two datasets 

were merged to create an overall uranium dataset. The 238U data were converted to activity units 

assuming an activity of 0.4673 pCi/μg based on the specific activity of D-38 uranium [ORAUT 2013]

and merged with the 235U data. All activity values, including zero, less than zero, and less-than MDA, 

were used without modification for all years.

Beginning in July 1991, alpha spectrometry was used to analyze the urine samples for uranium, at 

which time results for 234U, 235U, and 238U were reported. Because all uranium activity was assumed to 

be 234U for the purposes of calculating dose, the activities of all three isotopes were summed and 

used as the total uranium activity.

The statistical analysis was performed on an annual basis using 126,523 records. Table A-5 in 

Attachment A lists the statistical analysis results for uranium.

For 2005 through 2008, the LANL IN VITRO DATA FEB 2009 table in the in vitro database [ORAUT 

2009a] was queried to identify all records with a nuclide type of “U-234,” “U-235,” or “U-238” and 

collection dates that ranged from the beginning of 2005 through the end of 2008. The ZNO, 

COLLECTED_DATE, SAMPLE_ID, ACTIVITY_PS and ACTIVITY fields were extracted and exported 

to a spreadsheet. For a given SAMPLE_ID, the ACTIVITY_PS field was used as the sample activity 

unless it was blank, in which case the value in the ACTIVITY field was used as the result. All samples 

were 24-hour or simulated 24-hour samples and were in units of picocuries per sample or picocuries

per 24 hours. Therefore, all results were treated as picocuries per day. The 234U, 235U, and 238U

activities for a given SAMPLE_ID were summed and used as the total uranium activity. All data were 

used.

3.8 CESIUM-137

The TBL_NIOSH_REPORT_2007_V2 table in the in vivo database [ORAUT 2007] was queried to 

identify all records with a nuclide type of “Cs-137,” organ type of “Whole Body,” collection dates that 

ranged from the beginning of 1970 through the end of 2004, and count reason other than “new hire.”

The count_date, zno, and abundance_nCi fields were extracted and exported to a spreadsheet. The 

zno field was used as the employee identifier and the abundance_nCi field was used as the value of 

the whole-body count.

Records with no abundance value were entered with an abundance equal to the MDA based on the 

assumption that the result was less than the MDA and because the MDA was typically less than the 

positive values recorded.
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 20 of 113

Due to the small number of distinct records (301), the statistical analysis was performed in 5- or 4-

year blocks: 1970 to 1974, 1975 to 1979, 1980 to 1984, 1985 to 1989, and 1990 to 1993. Table A-6 in 

Attachment A lists the statistical analysis results for 137Cs. Insufficient data were available for after 

1993 to permit analysis.

4.0 INTAKE MODELING

This section discusses intake modeling assumptions, intake fitting, and intake materials.

4.1 ASSUMPTIONS

Each result used in the intake calculations was assumed to have a normal distribution. A uniform 

absolute error of 1 was applied to all results, thus assigning the same weight to each result. IMBA 

requires results to be in units of activity per day; therefore, all urinalysis results were normalized as 

needed to 24-hour samples using 1,400 mL (the volume of urine excreted by Reference Man in a 

24-hour period).

Because of the nature of work at LANL, intakes could have been either chronic or acute. However, a 

series of acute intakes can be approximated as a chronic intake. Therefore, intakes were assumed to 

be chronic and were assumed to occur through inhalation with a default breathing rate of 1.2 m3

/hr 

and a 5-μm activity median aerodynamic diameter particle size distribution.

For intake modeling purposes, all uranium activity was assumed to be 234U. This assumption does not 

affect the fitting of the data for intake determination because all uranium isotopes have the same 

biokinetic behavior and the isotopes considered in this analysis all have long half-lives in relation to 

the assumed intake period. International Commission on Radiological Protection (ICRP) Publication 

68 dose coefficients (also referred to as dose conversion factors) for 234U are 7% to 31% larger than 

the dose coefficients for 235U, 236U, and 238U [ICRP 1995]. Therefore, the assumption that the intake 

was 100% 234U provides a result that is favorable to claimants.

4.2 BIOASSAY FITTING

IMBA and the Internal Dosimetry Tool (IDOT) software were used to fit the bioassay results to a series 

of inhalation intakes. Data from 1945 through 2008 were fit as a series of chronic intakes.

The intake assumptions were based on patterns observed in the bioassay data. Periods with constant 

chronic intake rates were chosen by the selection of periods in which the bioassay results were 

similar. A new chronic intake period was started if the data indicated a significant sustained change in 

the bioassay results. By this method, the years from 1945 through 2008 were divided independently 

into multiple chronic intake periods for each radionuclide.

4.3 MATERIAL TYPES

ORAUT-TKBS-0010-5, Los Alamos National Laboratory – Occupational Internal Dose, discusses 

LANL internal dosimetry data for the dose reconstructor and includes guidance for the appropriate use 

of that information. Workers at LANL had the potential to receive intakes of 238Pu, 239Pu, uranium, 

polonium, tritium, and cesium. Site-specific internal dosimetry information for other radionuclides is 

rare or not available [ORAUT 2013].
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 21 of 113

4.3.1 Tritium

The dataset discussed in the previous section for tritium was condensed into a file for the period from

January 1, 1950, to December 31, 2008, with the following columns:

Days Post Conc MDA

Z Number ID Number Name 1/1/1950 uCi/L uCi/L

Duplicate records (i.e., lines that had all six fields the same as another line) were deleted to leave 

unique records. The doses were calculated for each individual and each calendar year from 1950 to 

2008.

Workers who had only a single urine result of <MDA μCi/L for a given period were not included in the 

calculations of the dose distribution for that period because they were not considered part of the 

routine monitoring program. All remaining concentrations of <MDA μCi/L were replaced with one-half 

of the appropriate MDA. Any person with a single measurement in a period was assigned a second

measurement 40 days later of one-half of the MDA of the first measurement.

The protocol given in ORAUT-OTIB-0011, Technical Information Bulletin: Tritium Calculated and 

Missed Dose Estimates, was used to calculate the dose for each individual with the following rules 

concerning the elapsed time between consecutive samples [ORAUT 2004b]: 

• Type 1 calculations were performed for samples separated by 40 or fewer days.

• Type 3 calculations were performed if there were no other samples within 90 days of a 

sample.

• Type 2 calculations were performed in all other situations.

The doses for a period were plotted on a lognormal probability plot and the typical parameters 

[geometric mean (GM), geometric standard deviation (GSD), and R2

] were determined from a linear 

regression. The plotting positions were calculated with i/n – 1/(2n) convention specified in ORAUTPROC-0095 [ORAUT 2006]. 

4.3.2 Plutonium-238

Plutonium-238 urinalysis results were analyzed with IMBA using type M and S materials to derive 

intake rates for 1968 to 2008. Note that absorption type SS is not applicable to 238Pu [ORAUT 2020]. 

Plutonium-238 Type M

The solid lines in Figures B-1 to B-8 and B-9 to B-15 show the individual fits to the 50th- and 

84th-percentile excretion rates, respectively, for type M materials. Figures B-16 and B-17 show the 

50th- and 84th-percentile predicted excretion rates, respectively, from all type M intakes. Table B-1 

lists the 50th- and 84th-percentile intake rates along with the associated GSDs determined from 238Pu 

urinalysis. 

Plutonium-238 Type S

The solid lines in Figures B-18 to B-24 and B-25 to B-31 show the individual fits to the 50th- and 

84th-percentile excretion rates, respectively, for type S materials. The same intake periods were 

applied for both percentiles because the values followed a similar pattern. Figures B-32 and B-33 

show the 50th- and 84th-percentile predicted excretion rates, respectively, from all type S intakes. 

Table B-2 lists the 50th- and 84th-percentile intake rates along with the associated GSDs determined 

from 238Pu urinalysis. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 22 of 113

4.3.3 Plutonium-239

Plutonium-239 urinalysis results were analyzed with IMBA and IDOT using type M, S, and SS

materials to derive intake rates for 1944 to 2008.

Plutonium-239 Type M Urinalysis

The solid lines in Figures B-34 to B-42 and B-43 to B-51 show the individual fits to the 50th- and 

84th-percentile excretion rates, respectively, for type M materials. The same intake periods were 

applied for both percentiles because the values followed a similar pattern. Figures B-52 and B-53 

show the 50th- and 84th-percentile predicted excretion rates, respectively, from all type M intakes. 

Table B-3 lists the 50th- and 84th-percentile intake rates along with the associated GSDs determined 

from 239Pu urinalysis.

Plutonium-239 Type S Urinalysis

The solid lines in Figures B-54 to B-62 and B-63 to B-71 show the individual fits to the 50th- and 

84th-percentile excretion rates, respectively, for type S materials. Figures B-72 and B-73 show the 

50th- and 84th-percentile predicted excretion rates, respectively, from all type S intakes. Table B-4 

lists the 50th- and 84th-percentile intake rates along with the associated GSDs determined from 239Pu 

urinalysis.

Plutonium-239 Type S Lung Counts

The solid lines in Figures B-74 to B-78 and B-79 to B-83 show the individual fits to the 50th- and 84thpercentile lung burdens, respectively, for type S materials. The same intake periods were applied for 

both percentiles as the values followed a similar pattern. Table B-5 lists the 50th- and 84th-percentile 

intake rates along with the associated GSDs determined from 239Pu lung burdens.

Plutonium-239 Type SS Urinalysis

The solid lines in Figures B-84 to B-92 and B-93 to B-101 show the individual fits to the 50th- and 

84th-percentile excretion rates, respectively, for type SS materials. Figures B-102 and B-103 show the 

50th- and 84th-percentile predicted excretion rates, respectively, from all type SS intakes. Table B-6

lists the 50th- and 84th-percentile intake rates along with the associated GSDs determined from 239Pu 

urinalysis.

Plutonium-239 Type SS Lung Counts

The solid lines in Figures B-104 to B-108 and B-109 to B-113 show the individual fits to the 50th- and 

84th-percentile lung burdens, respectively, for type SS materials. The same intake periods were 

applied for both percentiles as the values followed a similar pattern. Table B-7 lists the 50th- and 84thpercentile intake rates along with the associated GSDs determined from 239Pu lung burdens.

4.3.4 Polonium

Polonium urinalysis results were analyzed with IMBA using type F and M materials to derive intake 

rates for 1947 to 1956.

Polonium Type F

The solid lines in Figures B-114 and B-115 show the fit to the 50th- and 84th-percentile excretion 

rates, respectively, for type F materials. Table B-8 lists the 50th- and 84th-percentile intake rates 

along with the associated GSDs determined from the polonium urinalysis.

Polonium Type M

The solid lines in Figures B-116 and B-117 show the fit to the 50th- and 84th-percentile excretion 

rates, respectively, for type M materials. Table B-9 lists the 50th- and 84th-percentile intake rates 

along with the associated GSDs determined from the polonium urinalysis.
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 23 of 113

August 1, 1955, Incident

The bioassay data for the seven individuals positively identified as having been involved in this 

incident were analyzed separately using standard dose reconstruction bioassay fitting methods 

assuming both type F and type M material types. Figures B-118 through B-124 and B-125 through 

B-131 show the fits for each individual for type F and M material types respectively. Table B-10 lists 

the calculated intakes from these fits.

1944 to 1946

Polonium bioassay data to evaluate co-exposure intakes is not available for this period. To 

approximate intakes during this period, which falls within a Special Exposure Cohort (SEC) definition, 

the intake rate for each absorption type for 1947 to 1949 was applied.

4.3.5 Uranium

Because the uranium isotopes present at LANL have very long radiological half-lives, and because 

the material is retained in the body for long periods, excretion results are not independent. For 

example, an intake in the 1950s could contribute to urinary excretion in the 1980s and later. To avoid 

potential underestimation of intakes for people who worked at Los Alamos National Laboratory for 

relatively short periods, each chronic intake was fit independently using only the bioassay results from 

the single intake period for type S materials. This method results in an overestimate of intakes for 

exposures that extended through multiple assumed intake periods. Only the results in the intake 

period were selected for use in the fitting of each period. Excluded results are shown in light gray in 

the figures. For type M and F materials, this approach was not used.

Uranium Type F

The solid lines in Figures B-132 and B-133 show the fit to the 50th- and 84th-percentile excretion 

rates, respectively, for type F materials. Table B-11 lists the 50th- and 84th-percentile intake rates 

along with the associated GSDs determined from the uranium urinalysis.

Uranium Type M

The solid lines in Figures B-134 and B-135 show the fit to the 50th- and 84th-percentile excretion 

rates, respectively, for type M materials. Table B-12 lists the 50th- and 84th-percentile intake rates 

along with the associated GSDs determined from the uranium urinalysis.

Uranium Type S

The solid lines in Figures B-136 to B-142 and B-143 to B-149 show the individual fits to the 50th- and 

84th-percentile excretion rates, respectively, for type S materials. The same intake periods were 

applied for both percentiles because the values followed a similar pattern. Figures B-150 and B-151 

show the 50th- and 84th-percentile predicted excretion rates, respectively, from all type S intakes. 

Table B-13 lists the 50th- and 84th-percentile intake rates along with the associated GSDs determined 

from the uranium urinalysis.

1947 to 1949

Uranium bioassay data to evaluate co-exposure intakes is not available for this period. To 

approximate intakes during this period, which falls within a SEC definition, the intake rate for each 

absorption type for 1950 to 1955 was applied.

4.3.6 Cesium-137

Cesium whole-body count results were analyzed with IMBA using type F materials to derive intake 

rates for 1970 through 1993. The solid lines in Figures B-152 and B-153 show the fit to the 50th- and 

84th-percentile excretion rates, respectively, for type F materials. Table B-14 lists the 50th- and 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 24 of 113

84th-percentile intake rates along with the associated GSDs determined from the cesium whole-body 

counts. 

5.0 ASSIGNING INTAKES AND DOSES

This section describes the derived intake rates and provides guidance for assigning doses.

5.1 INTAKE RATE SUMMARY

For the calculation of doses to individuals from bioassay data, a GSD of 3 has been used to account 

for biological variation and uncertainty in the models. It was considered inappropriate to assign a 

value less than 3 for the co-exposure data. Therefore, a GSD of at least 3 was assigned for each of 

the intake periods. The GSDs for different intake periods have been conservatively adjusted for 

consistency between intake periods for calculational efficiency.

The following subsections list the intake rates that should be used for each radionuclide and the 

period of applicability of each intake rate except that for tritium. For tritium, the actual dose that should 

be used is provided.

5.2 TRITIUM

Table 5-1 lists the tritium doses and GSDs to be used for each year of potential tritium exposure.

Table 5-1. Tritium annual doses (mrem) and GSDs. 

Year Dose GSD

1950 33 7.2

1951 36 5.9

1952 25 4.2

1953 26 6.7

1954 16 6.2

1955 43 6.5

1956 33 6.9

1957 35 6.9

1958 26 5.7

1959 22 5.5

1960 27 5.2

1961 20 4.7

1962 17 4.7

1963 18 3.7

1964 17 3.5

1965 18 3.5

1966 19 4.2

1967 23 6.0

1968 16 4.6

1969 21 5.0

1970 25 7.0

1971 16 4.9

1972 14 5.4

1973 16 5.3

1974 25 6.7

1975 19 6.2

1976 13 4.1

1977 20 5.5

1978 20 5.2

1979 12 4.9

Year Dose GSD

1980 15 4.1

1981 17 4.1

1982 21 4.5

1983 18 4.8

1984 16 3.4

1985 18 3.3

1986 21 3.8

1987 17 4.3

1988 7 4.4

1989 7 3.5

1990 6 3.2

1991 2 3.0

1992 5 3.5

1993 6 3.4

1994 3 3.0

1995 5 3.0

1996 5 3.0

1997 4 3.0

1998 7 3.0

1999 4 3.0

2000 9 4.1

2001 6 3.0

2002 6 3.5

2003 5 3.3

2004 3 3.0

2005 3 3.0

2006 4 3.0

2007 4 3.0

2008 6 3.3
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 25 of 113

5.3 PLUTONIUM-238

Intakes of 238Pu should be assigned if the worker is known or believed to have been exposed to heat 

source plutonium. For heat source plutonium, absorption type SS is not applicable. If the worker was 

exposed only to weapons-grade plutonium (239Pu), the intake of 238Pu should be based on the isotope 

mixture for weapons-grade 239Pu and the 239Pu intakes given in Section 5.4 and not on the intakes in 

this section. Table 5-2 lists the 238Pu intakes and associated GSDs to be used for each year of 

potential 238Pu exposure for both type M and type S material. Absorption type SS is not applicable to 

238Pu [ORAUT 2020]. 

Table 5-2. Plutonium-238 type M and S intake rates (pCi/d). 

Start End

Type M 

50th percentile

Type M 

GSD

Type S 

50th percentile

Type S 

GSD

01/01/1968 12/31/1971 1.8 5.63 43 5.74

01/01/1972 12/31/1972 14. 3.13 765 3.13

01/01/1973 12/31/1974 2.0 4.31 72 4.17

01/01/1975 12/31/1977 0.67 3.59 5.2 8.47

01/01/1978 12/31/1981 0.32 7.56 5.2 8.47

01/01/1982 12/31/1988 0.084 8.73 1.8 8.47

01/01/1989 12/31/1993 0.44 4.31 9.7 4.17

01/01/1994 12/31/2008 0.048 6.82 0.72 6.58

5.4 PLUTONIUM-239

Intakes of 239Pu should be assigned if the worker is known or believed to have been exposed to 

weapons-grade plutonium. For weapons-grade plutonium, absorption type SS must be considered. If 

the worker was exposed only to heat source plutonium (238Pu), the plutonium intake should be based 

on the 238Pu intakes in Section 5.3 and not on the intakes in this section. Tables 5-3 through 5-5 list 

the 239Pu intakes and associated GSDs to be used for each year of potential 239Pu exposure for 

material types M, S, and SS respectively. Intakes of the associated isotopes as given in Table 5-9 of 

the LANL internal technical basis document [ORAUT 2013] must also be assigned.

Table 5-3. Plutonium-239 type M intake rates (pCi/d). 

Start End 50th percentile GSD

01/01/1944 12/31/1945 248 5.05

01/01/1946 12/31/1946 95 6.24

01/01/1947 12/31/1953 10 5.16

01/01/1954 12/31/1954 3.1 17.2

01/01/1955 12/31/1956 3.1 12.4

01/01/1957 12/31/1966 0.38 12.4

01/01/1967 12/31/1972 3.3 4.81

01/01/1973 12/31/1975 1.5 6.21

01/01/1976 12/31/1993 0.16 6.83

01/01/1994 12/31/2008 0.013 12.2
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 26 of 113

Table 5-4. Plutonium-239 type S intake rates (pCi/d). 

Start End 50th percentile GSD

01/01/1944 12/31/1945 8,651 5.05

01/01/1946 12/31/1946 5,125 6.24

01/01/1947 12/31/1953 200 4.87

01/01/1954 12/31/1954 88 11.12

01/01/1955 12/31/1956 88 15.3

01/01/1957 12/31/1966 6.3 11.91

01/01/1967 12/31/1968 73 4.62

01/01/1969 12/31/1971 27.66 4.50

01/01/1972 12/31/1974 29.43 4.50

01/01/1975 12/31/1975 41 6.34

01/01/1976 12/31/1993 2.3 6.34

01/01/1994 12/31/2008 0.14 12.8

Table 5-5. Plutonium-239 type SS intake rates (pCi/d). 

Start End 50th percentile GSD

01/01/1944 12/31/1945 51,900 5.05

01/01/1946 12/31/1946 11,200 6.21

01/01/1947 12/31/1953 1,460 5.13

01/01/1954 12/31/1954 437 17.14

01/01/1955 12/31/1956 437 12.06

01/01/1957 12/31/1966 52 12.21

01/01/1967 12/31/1968 452 4.82

01/01/1969 12/31/1971 24.4 4.30

01/01/1972 12/31/1974 25.9 4.52

01/01/1975 12/31/1975 214 6.21

01/01/1976 12/31/1977 21.1 6.82

01/01/1978 12/31/1979 17.1 5.19

01/01/1980 12/31/1993 21.1 6.82

01/01/1994 12/31/2008 1.69 11.83

5.5 POLONIUM

Table 5-6 lists the polonium intakes and associated GSDs to be used for each year of potential 

polonium exposure. 

Table 5-6. Polonium type F and M intake rates (pCi/d). 

Start End

Type F 

50th percentile

Type F 

GSD

Type M 

50th percentile

Type M 

GSD

01/01/1944 12/31/1946 592.8a 6.96 2013a 7.01

01/01/1947 03/31/1949 592.8 6.96 2013 7.01

04/01/1949 12/31/1956 592.8 3.00 2013 3.00

a. Intakes for 1944 through 1946 are based on the 1947 to March 31, 1949, intakes.

Dose reconstruction for individuals who were involved in the polonium incident that occurred at or 

near the beginning of August 1955 and who do not have relevant bioassay data, should be assigned 

the intakes in Table 5-7. The most favorable to claimant material type should be used. This intake 

should be applied only to individuals for whom there is evidence or reason to believe that they were 

involved in this incident.
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 27 of 113

Table 5-7. August 1, 1955, incident type F and M polonium intakes 

(pCi). 

Date

Type F 

50th percentile

Type F 

GSD

Type M 

50th percentile

Type M 

GSD

08/01/1955 2.8E6 3.00 1.2E7 3.00

5.6 URANIUM

Table 5-8 lists the uranium intakes and associated GSDs to be used for each year of potential 

uranium exposure. 

Table 5-8. Uranium types F, M, and S intake rates (pCi/d). 

Start End

Type F 

50th percentile

Type F 

GSD

Type M 

50th percentile

Type M 

GSD

Type S 

50th percentile

Type S 

GSD

01/01/1947 12/31/1949 21.3a 3.36 88.7a 3.36 1,520a 3.24

01/01/1950 12/31/1955 21.3 3.36 88.7 3.36 1,520 3.24

01/01/1956 12/31/1957 5.36 3.36 16.0 3.36 656 3.24

01/01/1958 12/31/1965 1.98 4.81 7.95 4.90 141 4.71

01/01/1966 12/31/1973 0.909 6.84 3.53 7.03 59.3 6.59

01/01/1974 12/31/1982 0.227 11.31 1.03 10.6 19.7 9.27

01/01/1983 12/31/1989 1.53 4.81 6.29 4.90 105 4.44

01/01/1990 12/31/2000 0.201 4.03 0.756 4.06 11.0 4.57

01/01/2001 12/31/2001 1.019 3.00 4.70 3.00 92.0 3.00

01/01/2002 12/31/2008 0.201 4.03 0.756 4.06 11.0 4.57

a. Intakes for 1947 through 1949 are based on the 1950 through 1955 intakes.

5.7 CESIUM-137

Table 5-9 lists the cesium intakes and associated GSDs to be used for each year of potential cesium 

exposure.

Table 5-9. Type F 137Cs intake rates (pCi/d). 

Start End

Type F

50th percentile

Type F

GSD

01/01/1970 12/31/1974 185.5 3.00

01/01/1975 12/31/1979 130.7 3.28

01/01/1980 12/31/1984 69.47 3.00

01/01/1985 12/31/1989 47.36 3.00

01/01/1990 12/31/1993 30.16 3.00

6.0 ATTRIBUTIONS AND ANNOTATIONS

All information requiring identification was addressed via references integrated into the reference 

section of this document.
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 28 of 113

REFERENCES

Hickman AW, Griffith WC, Roessler GS, and Guilmette RA [1995]. Application of a canine 238Pu

biokinetics/dosimetry model to human bioassay data. Health Phys 68(3):359–370. [SRDB Ref ID:

167452]

ICRP [1995]. Dose coefficients for intakes of radionuclides by workers. ICRP Publication 68. Ann 

ICRP 34(4). [SRDB Ref ID: 22731]

Inkret B, Miller G [1995]. On the front lines: plutonium workers past and present share their

experiences. Los Alamos Science No. 23. Los Alamos National Laboratory, Los Alamos, NM:

University of California. [SRDB Ref ID: 43568]

James AC, Filipy RE, Russell JJ, and McInroy JF [2003]. USTUR case 0259 whole body donation: a

comprehensive test of the current ICRP models for the behavior of inhaled 238PuO2 ceramic particles.

Health Phys 84(1). [SRDB Ref ID: 77731]

ORAUT [2004a]. Coworker data exposure profile development. ORAUT-PLAN-0014 Rev. 00. Oak

Ridge, TN: Oak Ridge Associated Universities Team. November 24. [SRDB Ref ID: 166559]

ORAUT [2004b]. Technical information bulletin: tritium calculated and missed dose estimates.

ORAUT-OTIB-0011 Rev. 00. Oak Ridge, TN: Oak Ridge Associated Universities Team. June 29.

[SRDB Ref ID: 19430]

ORAUT [2005]. Analysis of coworker bioassay data for internal dose assignment. ORAUT-OTIB-0019 

Rev. 01. Oak Ridge, TN: Oak Ridge Associated Universities Team. October 7. [SRDB Ref ID: 19438]

ORAUT [2006]. Generating summary statistics for coworker bioassay data. ORAUT-PROC-0095 

Rev. 00. Oak Ridge, TN: Oak Ridge Associated Universities Team. June 5. [SRDB Ref ID: 73397]

ORAUT [2007]. LANL in vivo data. Database. Oak Ridge, TN: Oak Ridge Associated Universities

Team. October 8. [SRDB Ref ID: 175106]

ORAUT [2009a]. LANL co-worker data Rev. 1. Database. Oak Ridge, TN: Oak Ridge Associated

Universities Team. February. [SRDB Ref ID: 175107]

ORAUT [2009b]. LANL in vitro dataset February 2009. Database. Oak Ridge, TN: Oak Ridge 

Associated Universities Team. February. [SRDB Ref ID: 175108]

ORAUT [2013]. Los Alamos National Laboratory – occupational internal dose. ORAUT-TKBS-0010-5 

Rev. 02. Oak Ridge, TN: Oak Ridge Associated Universities Team. April 18. [SRDB Ref ID: 124166]

ORAUT [2017]. Mound Site – occupational internal dose. ORAUT-TKBS-0016-5 Rev. 03. Oak Ridge,

TN: Oak Ridge Associated Universities Team. March 3. [SRDB Ref ID: 165903]

ORAUT [2020]. Estimating doses for plutonium strongly retained in the lung. ORAUT-OTIB-0049 Rev. 

02. Oak Ridge, TN: Oak Ridge Associated Universities Team. September 1. [SRDB Ref ID: 178329]

Various authors [1976–1980]. Chelation DTPA data for DOE Employees - 

REAC_TS_DTPA_210.0001_Charlie Arnold. [SRDB Ref ID: 71439]
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 29 of 113

ATTACHMENT A 

CO-EXPOSURE DATA TABLES

LIST OF TABLES

TABLE TITLE PAGE

A-1 Statistical summary of 238Pu urinary excretion rates, 1968 to 2008......................................... 30

A-2 Statistical summary of 239Pu urinary excretion rates, 1945 to 2008......................................... 31

A-3 Statistical summary of 239Pu lung burdens, 1969 to 1979 ....................................................... 31

A-4 Statistical summary of polonium urinary excretion rates, 1947 to 1956 .................................. 32

A-5 Statistical summary of uranium urinary excretion rates, 1950 to 2008.................................... 33

A-6 Statistical summary of cesium whole-body counts, 1970 to 1993........................................... 33
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 30 of 113

ATTACHMENT A

CO-EXPOSURE DATA TABLES

Table A-1. Statistical summary of 238Pu urinary excretion rates (pCi/d), 1968 

to 2008. 

Effective 

bioassay 

date

GM

(50th)

GM × GSD

(84th)

07/01/1968 0.00823 0.0339

07/01/1969 0.00486 0.0332

07/01/1970 0.00147 0.0062

07/01/1971 0.00815 0.0466

07/01/1972 0.02683 0.0840

07/01/1973 0.00581 0.0308

07/01/1974 0.00571 0.0214

07/01/1975 0.00261 0.0154

07/01/1976 0.00224 0.0164

07/01/1977 0.00232 0.0182

07/01/1978 0.00101 0.0143

07/01/1979 0.00162 0.0118

07/01/1980 0.00126 0.0091

07/01/1981 0.00124 0.0118

07/01/1982 0.00010 0.0027

07/01/1983 0.00010 0.0019

07/01/1984 0.00011 0.0026

07/01/1985 0.00028 0.0038

07/01/1986 0.00079 0.0053

07/01/1987 0.00056 0.0047

07/01/1988 0.00072 0.0048

Effective 

bioassay 

date

GM

(50th)

GM × GSD

(84th)

07/01/1989 0.0017 0.0079

07/01/1990 0.0021 0.0081

07/01/1991 0.0025 0.0091

07/01/1992 0.0022 0.0079

07/01/1993 0.0016 0.0078

07/01/1994 0.0006 0.0046

07/01/1995 0.0003 0.0049

07/01/1996 0.0006 0.0035

07/01/1997 0.0004 0.0035

07/01/1998 0.0004 0.0029

07/01/1999 0.0002 0.0013

07/01/2000 0.0002 0.0028

07/01/2001 0.0002 0.0017

07/01/2002 0.0002 0.0012

07/01/2003 0.0002 0.0011

07/01/2004 0.0003 0.0016

07/01/2005 0.0005 0.0022

07/01/2006 0.0007 0.0031

07/01/2007 0.0004 0.0042

07/01/2008 0.0005 0.0029
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 31 of 113

ATTACHMENT A

CO-EXPOSURE DATA TABLES

Table A-2. Statistical summary of 239Pu urinary excretion rates (pCi/d), 1945 to 

2008. 

Effective 

bioassay 

date

GM 

(50th)

GM × GSD 

(84th)

07/01/1945 0.8332 4.2106

07/01/1946 0.1793 1.1191

07/01/1947 0.1065 0.4876

07/01/1948 0.0571 0.4084

07/01/1949 0.0301 0.2028

07/01/1950 0.0434 0.2118

07/01/1951 0.0574 0.2595

07/01/1952 0.0628 0.4073

07/01/1953 0.0703 0.4009

07/01/1954 0.0153 0.1779

07/01/1955 0.0119 0.0978

07/01/1956 0.0115 0.0979

07/01/1957 0.0042 0.052

07/01/1958 0.0040 0.0537

07/01/1959 0.0020 0.0322

07/01/1960 0.0022 0.0306

07/01/1961 0.0019 0.0201

07/01/1962 0.0016 0.0232

07/01/1963 0.002 0.0306

07/01/1964 0.0026 0.0265

07/01/1965 0.0023 0.0253

07/01/1966 0.0037 0.0380

07/01/1967 0.0066 0.0471

07/01/1968 0.0093 0.0584

07/01/1969 0.0145 0.0814

07/01/1970 0.0066 0.0422

07/01/1971 0.0157 0.1008

07/01/1972 0.0341 0.1136

07/01/1973 0.0083 0.0446

07/01/1974 0.0061 0.0350

07/01/1975 0.0037 0.0265

07/01/1976 0.0022 0.0201

Effective 

bioassay 

date

GM 

(50th)

GM × GSD 

(84th)

07/01/1977 0.0023 0.0292

07/01/1978 0.0012 0.0157

07/01/1979 0.0011 0.0116

07/01/1980 0.0018 0.0154

07/01/1981 0.0014 0.0137

07/01/1982 0.0003 0.0057

07/01/1983 0.0006 0.0093

07/01/1984 0.0003 0.0053

07/01/1985 0.0017 0.0111

07/01/1986 0.0013 0.0108

07/01/1987 0.0013 0.0084

07/01/1988 0.0012 0.0071

07/01/1989 0.0017 0.0077

07/01/1990 0.0021 0.0083

07/01/1991 0.0023 0.0084

07/01/1992 0.0017 0.0076

07/01/1993 0.0015 0.0083

07/01/1994 0.0004 0.0045

07/01/1995 0.0003 0.0043

07/01/1996 0.0007 0.0040

07/01/1997 0.0002 0.0038

07/01/1998 0.0002 0.0026

07/01/1999 0.00010 0.00120

07/01/2000 0.00009 0.00136

07/01/2001 0.00004 0.00094

07/01/2002 0.00003 0.00064

07/01/2003 0.00002 0.00034

07/01/2004 0.00002 0.00041

07/01/2005 0.00004 0.00049

07/01/2006 0.00002 0.00035

07/01/2007 0.00004 0.00051

07/01/2008 0.00006 0.00068

Table A-3. Statistical summary of 239Pu lung burdens (pCi), 1969 

to 1979. 

Measurement 

data date range

Effective 

bioassay date

GM

(50th)

GM × GSD 

(84th)

1969–1970 07/01/1970 473 2,033

1971–1974 07/01/1973 504 2,268

1975 07/01/1975 3,712 6,922

1976–1977 01/01/1977 1,221 4,319

1978–1979 01/01/1979 248 1,290
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 32 of 113

ATTACHMENT A

CO-EXPOSURE DATA TABLES

Table A-4. Statistical summary of polonium urinary excretion rates (pCi/d), 

1947 to 1956. 

Effective 

bioassay 

date

GM

(50th)

GM × GSD

(84th)

02/15/1947 54.51 219.82

05/15/1947 76.59 343.47

08/15/1947 25.15 240.80

11/15/1947 50.89 200.17

02/15/1948 48.88 252.94

05/15/1948 52.76 294.13

08/15/1948 98.45 507.63

11/15/1948 53.79 189.88

02/15/1949 79.84 364.04

05/15/1949 49.10 148.29

08/15/1949 32.53 86.43

11/15/1949 29.78 120.96

02/15/1950 20.90 63.53

05/15/1950 41.23 90.29

08/15/1950 25.93 79.71

11/15/1950 31.89 119.93

02/15/1951 42.18 115.02

05/15/1951 33.14 111.07

08/15/1951 41.25 144.68

Effective 

bioassay 

date

GM

(50th)

GM × GSD

(84th)

11/15/1951 36.96 125.69

02/15/1952 45.76 142.02

05/15/1952 32.36 157.48

08/15/1952 27.83 105.86

11/15/1952 27.15 84.03

02/15/1953 76.61 299.93

05/15/1953 33.87 127.48

08/15/1953 51.79 138.64

11/15/1953 65.50 225.54

02/15/1954 43.99 122.20

05/15/1954 46.75 120.15

08/15/1954 39.35 89.36

11/15/1954 34.75 76.77

02/15/1955 33.08 77.69

05/15/1955 16.99 52.10

08/15/1955 55.54 200.24

11/15/1955 30.19 54.61

07/01/1956 14.44 52.33
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 33 of 113

ATTACHMENT A

CO-EXPOSURE DATA TABLES

Table A-5. Statistical summary of uranium urinary excretion rates (pCi/d), 

1950 to 2008. 

Effective 

bioassay 

date

GM

(50th)

GM × GS

D (84th)

07/01/1950 6.941 24.394

07/01/1951 5.035 15.898

07/01/1952 6.764 19.354

07/01/1953 3.979 11.575

07/01/1954 5.656 20.846

07/01/1955 6.536 18.864

07/01/1956 1.447 5.702

07/01/1957 1.518 4.324

07/01/1958 0.410 2.087

07/01/1959 0.090 1.110

07/01/1960 0.083 0.660

07/01/1961 0.206 1.498

07/01/1962 0.723 4.006

07/01/1963 0.471 2.691

07/01/1964 1.009 3.153

07/01/1965 0.722 3.779

07/01/1966 0.467 2.249

07/01/1967 0.356 3.554

07/01/1968 0.065 0.919

07/01/1969 0.204 1.287

07/01/1970 0.224 1.370

07/01/1971 0.001 0.044

07/01/1972 0.150 1.046

07/01/1973 0.233 1.501

07/01/1974 0.070 0.876

07/01/1975 0.080 0.784

07/01/1976 0.040 0.529

07/01/1977 0.023 0.391

07/01/1978 0.034 0.513

07/01/1979 0.055 0.590

Effective 

bioassay 

date

GM

(50th)

GM × GS

D (84th)

07/01/1980 0.002 0.054

07/01/1981 0.003 0.060

07/01/1982 0.016 0.274

07/01/1983 0.438 2.136

07/01/1984 0.410 1.788

07/01/1985 0.215 1.045

07/01/1986 0.482 1.723

07/01/1987 0.286 1.893

07/01/1988 0.348 1.543

07/01/1989 0.317 1.351

07/01/1990 0.030 0.240

10/01/1991 0.058 0.231

07/01/1992 0.024 0.168

07/01/1993 0.033 0.223

07/01/1994 0.074 0.346

07/01/1995 0.084 0.399

07/01/1996 0.088 0.366

07/01/1997 0.072 0.292

07/01/1998 0.070 0.291

07/01/1999 0.064 0.307

07/01/2000 0.066 0.383

07/01/2001 0.285 0.746

07/01/2002 0.070 0.231

07/01/2003 0.053 0.164

07/01/2004 0.059 0.197

07/01/2005 0.114 0.312

07/01/2006 0.078 0.230

07/01/2007 0.103 0.288

07/01/2008 0.074 0.216

Table A-6. Statistical summary of cesium whole-body counts 

(pCi), 1970 to 1993. 

Measurement data 

date range

Effective 

bioassay date GM (50th)

GM × GSD 

(84th)

1970–1974 07/01/1972 12,740 37,156

1975–1979 07/01/1977 9,013 29,573

1980–1984 07/01/1982 4,799 9,442

1985–1989 01/01/1987 3,277 6,896

1990–1993 01/01/1992 2,089 4,354
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 34 of 113

ATTACHMENT B 

CO-EXPOSURE DATA FIGURES

LIST OF TABLES

TABLE TITLE PAGE

B-1 Summary of 238Pu type M intake rates and dates ................................................................... 50

B-2 Summary of 238Pu type S intake rates and dates.................................................................... 58

B-3 Summary of 239Pu type M intake rates and dates ................................................................... 68

B-4 Summary of 239Pu type S urinalysis-based intake rates and dates ......................................... 78

B-5 Summary of 239Pu type S lung burden-based intake rates and dates ..................................... 83

B-6 Summary of 239Pu type SS urinalysis-based intake rates and dates ....................................... 90

B-7 Summary of 239Pu type SS lung burden-based intake rates and dates ................................... 94

B-8 Summary of polonium type F intake rates and dates.............................................................. 94

B-9 Summary of polonium type M intake rates and dates ............................................................. 95

B-10 Summary of polonium acute intakes type F and M............................................................... 102

B-11 Summary of uranium type F intake rates and dates ............................................................. 103

B-12 Summary of uranium type M intake rates and dates............................................................. 104

B-13 Summary of uranium type S intake rates and dates ............................................................. 112

B-14 Summary of type F 137Cs intake rates and dates .................................................................. 113

LIST OF FIGURES

FIGURE TITLE PAGE

B-1 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1968 to 1971, 50th percentile, type M ....................... 42

B-2 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1972, 50th percentile, type M.................................... 42

B-3 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1973 to 1974, 50th percentile, type M ....................... 43

B-4 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1975 to 1977, 50th percentile, type M ....................... 43

B-5 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1978 to 1981, 50th percentile, type M ....................... 44

B-6 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1982 to 1988, 50th percentile, type M ....................... 44

B-7 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1989 to 1993, 50th percentile, type M ....................... 45

B-8 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1994 to 2008, 50th percentile, type M ....................... 45

B-9 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1968 to 1971, 84th percentile, type M ....................... 46

B-10 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1972, 84th percentile, type M.................................... 46

B-11 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1973 to 1974, 84th percentile, type M ....................... 47

B-12 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1975 to 1981, 84th percentile, type M ....................... 47

B-13 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1982 to 1988, 84th percentile, type M ....................... 48
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 35 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

B-14 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1989 to 1993, 84th percentile, type M ....................... 48

B-15 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1994 to 2008, 84th percentile, type M ....................... 49

B-16 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots) from all intakes, 50th percentile, type M ..................... 49

B-17 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots) from all intakes, 84th percentile, type M..................... 50

B-18 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1968 to 1971, 50th percentile, type S........................ 50

B-19 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1972, 50th percentile, type S .................................... 51

B-20 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1973 to 1974, 50th percentile, type S........................ 51

B-21 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1975 to 1981, 50th percentile, type S........................ 52

B-22 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1982 to 1988, 50th percentile, type S........................ 52

B-23 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1989 to 1993, 50th percentile, type S........................ 53

B-24 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1994 to 2008, 50th percentile, type S........................ 53

B-25 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1968 to 1971, 84th percentile, type S........................ 54

B-26 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1972, 84th percentile, type S .................................... 54

B-27 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1973 to 1974, 84th percentile, type S........................ 55

B-28 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1975 to 1981, 84th percentile, type S........................ 55

B-29 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1982 to 1988, 84th percentile, type S........................ 56

B-30 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1989 to 1993, 84th percentile, type S........................ 56

B-31 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots), 1994 to 2008, 84th percentile, type S........................ 57

B-32 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots) from all intakes, 50th percentile, type S...................... 57

B-33 Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu intake rates (line) 

compared with bioassay results (dots) from all intakes, 84th percentile, type S...................... 58

B-34 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots), 1944 to 1945, 50th percentile, type M ....................... 58

B-35 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots), 1946, 50th percentile, type M.................................... 59

B-36 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots), 1947, 50th percentile, type M.................................... 59

B-37 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots), 1954 to 1956, 50th percentile, type M ....................... 60

B-38 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots), 1957 to 1966, 50th percentile, type M ....................... 60
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 36 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

B-39 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots), 1967 to 1972, 50th percentile, type M ....................... 61

B-40 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots), 1973 to 1975, 50th percentile, type M ....................... 61

B-41 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots), 1976 to 1993, 50th percentile, type M ....................... 62

B-42 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots), 1994 to 2008, 50th percentile, type M ....................... 62

B-43 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots), 1944 to 1945, 84th percentile, type M ....................... 63

B-44 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots), 1946, 84th percentile, type M.................................... 63

B-45 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots), 1947 to 1954, 84th percentile, type M ....................... 64

B-46 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots), 1955 to 1956, 84th percentile, type M ....................... 64

B-47 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots), 1957 to 1966, 84th percentile, type M ....................... 65

B-48 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots), 1967 to 1972, 84th percentile, type M ....................... 65

B-49 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots), 1973 to 1975, 84th percentile, type M ....................... 66

B-50 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots), 1976 to 1993, 84th percentile, type M ....................... 66

B-51 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots), 1994 to 2008, 84th percentile, type M ....................... 67

B-52 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots) from all intakes, 50th percentile, type M ..................... 67

B-53 Predicted 239Pu bioassay results calculated using IMBA-derived 239Pu intake rates (line) 

compared with bioassay results (dots) from all intakes, 84th percentile, type M ..................... 68

B-54 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1944 to 1945, 50th percentile, type S...... 68

B-55 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1946, 50th percentile, type S................... 69

B-56 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1947 to 1953, 50th percentile, type S...... 69

B-57 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1954 to 1956, 50th percentile, type S...... 70

B-58 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1957 to 1966, 50th percentile, type S...... 70

B-59 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1967 to 1972, 50th percentile, type S...... 71

B-60 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1973 to 1975, 50th percentile, type S...... 71

B-61 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1976 to 1993, 50th percentile, type S...... 72

B-62 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1994 to 2008, 50th percentile, type S...... 72

B-63 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1944 to 1945, 84th percentile, type S...... 73
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 37 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

B-64 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1946, 84th percentile, type S................... 73

B-65 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1947 to 1954, 84th percentile, type S...... 74

B-66 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1955 to 1956, 84th percentile, type S...... 74

B-67 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1957 to 1966, 84th percentile, type S...... 75

B-68 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1967 to 1972, 84th percentile, type S...... 75

B-69 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1973 to 1975, 84th percentile, type S...... 76

B-70 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1976 to 1993, 84th percentile, type S...... 76

B-71 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1994 to 2008, 84th percentile, type S...... 77

B-72 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots) from all intakes, 50th percentile, 

type S.....................................................................................................................................77

B-73 Predicted 239Pu urinalysis bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots) from all intakes, 84th percentile, 

type S.....................................................................................................................................78

B-74 Predicted 239Pu lung burden bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1969 to 1971, 50th percentile, type S...... 78

B-75 Predicted 239Pu lung burden bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1972 to 1974, 50th percentile, type S...... 79

B-76 Predicted 239Pu lung burden bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1975, 50th percentile, type S................... 79

B-77 Predicted 239Pu lung burden bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1976 to 1977, 50th percentile, type S...... 80

B-78 Predicted 239Pu lung burden bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1978 to 1979, 50th percentile, type S...... 80

B-79 Predicted 239Pu lung burden bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1969 to 1971, 84th percentile, type S...... 81

B-80 Predicted 239Pu lung burden bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1972 to 1974, 84th percentile, type S...... 81

B-81 Predicted 239Pu lung burden bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1975, 84th percentile, type S................... 82

B-82 Predicted 239Pu lung burden bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1976 to 1977, 84th percentile, type S...... 82

B-83 Predicted 239Pu lung burden bioassay results calculated using IMBA-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1978 to 1979, 84th percentile, type S...... 83

B-84 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1944 to 1945, 50th percentile, type 

SS..........................................................................................................................................83

B-85 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1946, 50th percentile, type SS ................ 84

B-86 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1947 to 1953, 50th percentile, type 

SS..........................................................................................................................................84
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 38 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

B-87 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1954 to 1956, 50th percentile, type 

SS..........................................................................................................................................84

B-88 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1957 to 1966, 50th percentile, type 

SS..........................................................................................................................................85

B-89 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1967 to 1972, 50th percentile, type 

SS..........................................................................................................................................85

B-90 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1973 to 1975, 50th percentile, type 

SS..........................................................................................................................................85

B-91 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1976 to 1993, 50th percentile, type 

SS..........................................................................................................................................86

B-92 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1994 to 2008, 50th percentile, type 

SS..........................................................................................................................................86

B-93 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1944 to 1945, 84th percentile, type 

SS..........................................................................................................................................86

B-94 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1946, 84th percentile, type SS ................ 87

B-95 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1947 to 1954, 84th percentile, type 

SS..........................................................................................................................................87

B-96 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake

rates (line) compared with bioassay results (dots), 1955 to 1956, 84th percentile, type 

SS..........................................................................................................................................87

B-97 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1957 to 1966, 84th percentile, type 

SS..........................................................................................................................................88

B-98 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1967 to 1972, 84th percentile, type 

SS..........................................................................................................................................88

B-99 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1973 to 1975, 84th percentile, type 

SS..........................................................................................................................................88

B-100 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1976 to 1993, 84th percentile, type 

SS..........................................................................................................................................89

B-101 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1994 to 2008, 84th percentile, type 

SS..........................................................................................................................................89

B-102 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots) from all intakes, 50th percentile, type 

SS..........................................................................................................................................89

B-103 Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots) from all intakes, 84th percentile, type 

SS..........................................................................................................................................90
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 39 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

B-104 Predicted 239Pu lung burden bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1969 to 1971, 50th percentile, type 

SS..........................................................................................................................................90

B-105 Predicted 239Pu lung burden bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1972 to 1974, 50th percentile, type 

SS..........................................................................................................................................91

B-106 Predicted 239Pu lung burden bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1975, 50th percentile, type SS ................ 91

B-107 Predicted 239Pu lung burden bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1976 to 1977, 50th percentile, type 

SS..........................................................................................................................................91

B-108 Predicted 239Pu lung burden bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1978 to 1979, 50th percentile, type 

SS..........................................................................................................................................92

B-109 Predicted 239Pu lung burden bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1969 to 1971, 84th percentile, type 

SS..........................................................................................................................................92

B-110 Predicted 239Pu lung burden bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1972 to 1974, 84th percentile, type 

SS..........................................................................................................................................92

B-111 Predicted 239Pu lung burden bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1975, 84th percentile, type SS ................ 93

B-112 Predicted 239Pu lung burden bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1976 to 1977, 84th percentile, type 

SS..........................................................................................................................................93

B-113 Predicted 239Pu lung burden bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1978 to 1979, 84th percentile, type 

SS..........................................................................................................................................93

B-114 Predicted polonium bioassay results calculated using IMBA-derived polonium intake 

rates (line) compared with bioassay results (dots) from all intakes, 50th percentile, type F .... 94

B-115 Predicted polonium bioassay results calculated using IMBA-derived polonium intake 

rates (line) compared with bioassay results (dots) from all intakes, 84th percentile, type F .... 94

B-116 Predicted polonium bioassay results calculated using IMBA-derived polonium intake 

rates (line) compared with bioassay results (dots) from all intakes, 50th percentile, type 

M............................................................................................................................................95

B-117 Predicted polonium bioassay results calculated using IMBA-derived polonium intake 

rates (line) compared with bioassay results (dots) from all intakes, 84th percentile, type 

M............................................................................................................................................95

B-118 Predicted polonium acute intake bioassay fit calculated using an IMBA-derived polonium 

intake rate (line) compared with bioassay results (dots) for individual “A,” type F................... 96

B-119 Predicted polonium acute intake bioassay fit calculated using an IMBA-derived polonium 

intake rate (line) compared with bioassay results (dots) for individual “B,” type F................... 96

B-120 Predicted polonium acute intake bioassay fit calculated using an IMBA-derived polonium 

intake rate (line) compared with bioassay results (dots) for individual “C,” type F................... 97

B-121 Predicted polonium acute intake bioassay fit calculated using an IMBA-derived polonium 

intake rate (line) compared with bioassay results (dots) for individual “D,” type F................... 97

B-122 Predicted polonium acute intake bioassay fit calculated using an IMBA-derived polonium 

intake rate (line) compared with bioassay results (dots) for individual “E,” type F................... 98

B-123 Predicted polonium acute intake bioassay fit calculated using an IMBA-derived polonium 

intake rate (line) compared with bioassay results (dots) for individual “F,” type F ................... 98
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 40 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

B-124 Predicted polonium acute intake bioassay fit calculated using an IMBA-derived polonium 

intake rate (line) compared with bioassay results (dots) for individual “G,” type F .................. 99

B-125 Predicted polonium acute intake bioassay fit calculated using an IMBA-derived polonium 

intake rate (line) compared with bioassay results (dots) for individual “A,” type M .................. 99

B-126 Predicted polonium acute intake bioassay fit calculated using an IMBA-derived polonium 

intake rate (line) compared with bioassay results (dots) for individual “B,” type M ................ 100

B-127 Predicted polonium acute intake bioassay fit calculated using an IMBA-derived polonium 

intake rate (line) compared with bioassay results (dots) for individual “C,” type M................ 100

B-128 Predicted polonium acute intake bioassay fit calculated using an IMBA-derived polonium 

intake rate (line) compared with bioassay results (dots) for individual “D,” type M................ 101

B-129 Predicted polonium acute intake bioassay fit calculated using an IMBA-derived polonium 

intake rate (line) compared with bioassay results (dots) for individual “E,” type M ................ 101

B-130 Predicted polonium acute intake bioassay fit calculated using an IMBA-derived polonium 

intake rate (line) compared with bioassay results (dots) for individual “F,” type M ................ 102

B-131 Predicted polonium acute intake bioassay fit calculated using an IMBA-derived polonium 

intake rate (line) compared with bioassay results (dots) for individual “G,” type M................ 102

B-132 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots) from all intakes, 50th percentile, type F........... 103

B-133 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots) from all intakes, 84th percentile, type F........... 103

B-134 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots) from all intakes, 50th percentile, type M .......... 104

B-135 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots) from all intakes, 84th percentile, type M .......... 104

B-136 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots), 1950 to 1955, 50th percentile, type S............. 105

B-137 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots), 1956 to 1957, 50th percentile, type S............. 105

B-138 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots), 1958 to 1965, 50th percentile, type S............. 106

B-139 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots), 1966 to 1973, 50th percentile, type S............. 106

B-140 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots), 1974 to 1982, 50th percentile, type S............. 107

B-141 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots), 1983 to 1989, 50th percentile, type S............. 107

B-142 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots), 1990 to 2008, 50th percentile, type S............. 108

B-143 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots), 1950 to 1955, 84th percentile, type S............. 108

B-144 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots), 1956 and 1957, 84th percentile, type S.......... 109

B-145 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots), 1958 to 1965, 84th percentile, type S............. 109

B-146 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots), 1966 to 1973, 84th percentile, type S............. 110

B-147 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots), 1974 to 1982, 84th percentile, type S............. 110

B-148 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots), 1983 to 1989, 84th percentile, type S............. 111
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 41 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

B-149 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots), 1990 to 2008, 84th percentile, type S............. 111

B-150 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots), all intake periods, 50th percentile, type S....... 112

B-151 Predicted uranium bioassay results calculated using IMBA-derived uranium intake rates 

(line) compared with bioassay results (dots), all intake periods, 84th percentile, type S....... 112

B-152 Predicted cesium bioassay results calculated using IMBA-derived cesium intake rates 

(line) compared with bioassay results (dots) from all intakes, 50th percentile, type F........... 113

B-153 Predicted cesium bioassay results calculated using IMBA-derived cesium intake rates 

(line) compared with bioassay results (dots) from all intakes, 84th percentile, type F........... 113
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 42 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-1. Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu 

intake rates (line) compared with bioassay results (dots), 1968 to 1971, 50th 

percentile, type M. 

Figure B-2. Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu 

intake rates (line) compared with bioassay results (dots), 1972, 50th percentile, 

type M. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 43 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-3. Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu 

intake rates (line) compared with bioassay results (dots), 1973 to 1974, 50th 

percentile, type M. 

Figure B-4. Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu 

intake rates (line) compared with bioassay results (dots), 1975 to 1977, 50th 

percentile, type M. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 44 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-5. Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu 

intake rates (line) compared with bioassay results (dots), 1978 to 1981, 50th 

percentile, type M. 

Figure B-6. Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu 

intake rates (line) compared with bioassay results (dots), 1982 to 1988, 50th 

percentile, type M. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 45 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-7. Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu 

intake rates (line) compared with bioassay results (dots), 1989 to 1993, 50th 

percentile, type M. 

Figure B-8. Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu 

intake rates (line) compared with bioassay results (dots), 1994 to 2008, 50th 

percentile, type M. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 46 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-9. Predicted 238Pu bioassay results calculated using IMBA-derived 238Pu 

intake rates (line) compared with bioassay results (dots), 1968 to 1971, 84th 

percentile, type M. 

Figure B-10. Predicted 238Pu bioassay results calculated using IMBA-derived 

238Pu intake rates (line) compared with bioassay results (dots), 1972, 84th 

percentile, type M. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 47 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-11. Predicted 238Pu bioassay results calculated using IMBA-derived 

238Pu intake rates (line) compared with bioassay results (dots), 1973 to 1974, 84th 

percentile, type M. 

Figure B-12. Predicted 238Pu bioassay results calculated using IMBA-derived 

238Pu intake rates (line) compared with bioassay results (dots), 1975 to 1981, 84th 

percentile, type M. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 48 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-13. Predicted 238Pu bioassay results calculated using IMBA-derived 

238Pu intake rates (line) compared with bioassay results (dots), 1982 to 1988, 84th 

percentile, type M. 

Figure B-14. Predicted 238Pu bioassay results calculated using IMBA-derived 

238Pu intake rates (line) compared with bioassay results (dots), 1989 to 1993, 84th 

percentile, type M. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 49 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-15. Predicted 238

Pu bioassay results calculated using IMBA-derived 

238Pu intake rates (line) compared with bioassay results (dots), 1994 to 2008, 84th 

percentile, type M. 

Figure B-16. Predicted 238Pu bioassay results calculated using IMBA-derived 

238Pu intake rates (line) compared with bioassay results (dots) from all intakes, 

50th percentile, type M. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 50 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-17. Predicted 238Pu bioassay results calculated using IMBA-derived 

238Pu intake rates (line) compared with bioassay results (dots) from all intakes, 

84th percentile, type M. 

Table B-1. Summary of 238Pu type M intake rates (pCi/d) and dates. 

Start End 50th percentile 84th percentile GSD

01/01/1968 12/31/1971 1.774 9.981 5.63

01/01/1972 12/31/1972 14.12 44.22 3.13

01/01/1973 12/31/1974 2.038 8.793 4.31

01/01/1975 12/31/1977 0.666 2.394 3.59

01/01/1978 12/31/1981 0.317 2.394 7.56

01/01/1982 12/31/1988 0.084 0.737 8.74

01/01/1989 12/31/1993 0.439 1.764 4.02

01/01/1994 12/31/2008 0.048 0.326 6.82

Figure B-18. Predicted 238Pu bioassay results calculated using IMBA-derived 

238Pu intake rates (line) compared with bioassay results (dots), 1968 to 1971, 50th 

percentile, type S. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 51 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-19. Predicted 238Pu bioassay results calculated using IMBA-derived 

238Pu intake rates (line) compared with bioassay results (dots), 1972, 50th 

percentile, type S. 

Figure B-20. Predicted 238Pu bioassay results calculated using IMBA-derived 

238Pu intake rates (line) compared with bioassay results (dots), 1973 to 1974, 50th 

percentile, type S. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 52 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-21. Predicted 238Pu bioassay results calculated using IMBA-derived 

238Pu intake rates (line) compared with bioassay results (dots), 1975 to 1981, 50th 

percentile, type S. 

Figure B-22. Predicted 238Pu bioassay results calculated using IMBA-derived 

238Pu intake rates (line) compared with bioassay results (dots), 1982 to 1988, 50th 

percentile, type S. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 53 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-23. Predicted 238Pu bioassay results calculated using IMBA-derived 

238Pu intake rates (line) compared with bioassay results (dots), 1989 to 1993, 50th 

percentile, type S. 

Figure B-24. Predicted 238Pu bioassay results calculated using IMBA-derived 

238Pu intake rates (line) compared with bioassay results (dots), 1994 to 2008, 50th 

percentile, type S. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 54 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-25. Predicted 238Pu bioassay results calculated using IMBA-derived 

238Pu intake rates (line) compared with bioassay results (dots), 1968 to 1971, 84th 

percentile, type S. 

Figure B-26. Predicted 238Pu bioassay results calculated using IMBA-derived 

238Pu intake rates (line) compared with bioassay results (dots), 1972, 84th 

percentile, type S. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 55 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-27. Predicted 238Pu bioassay results calculated using IMBA-derived 

238Pu intake rates (line) compared with bioassay results (dots), 1973 to 1974, 84th 

percentile, type S. 

Figure B-28. Predicted 238Pu bioassay results calculated using IMBA-derived 

238Pu intake rates (line) compared with bioassay results (dots), 1975 to 1981, 84th 

percentile, type S. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 56 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-29. Predicted 238Pu bioassay results calculated using IMBA-derived 

238Pu intake rates (line) compared with bioassay results (dots), 1982 to 1988, 84th 

percentile, type S. 

Figure B-30. Predicted 238Pu bioassay results calculated using IMBA-derived 

238Pu intake rates (line) compared with bioassay results (dots), 1989 to 1993, 84th 

percentile, type S. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 57 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-31. Predicted 238Pu bioassay results calculated using IMBA-derived 

238Pu intake rates (line) compared with bioassay results (dots), 1994 to 2008, 84th 

percentile, type S. 

Figure B-32. Predicted 238Pu bioassay results calculated using IMBA-derived 

238Pu intake rates (line) compared with bioassay results (dots) from all intakes, 

50th percentile, type S. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 58 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-33. Predicted 238Pu bioassay results calculated using IMBA-derived 

238Pu intake rates (line) compared with bioassay results (dots) from all intakes, 

84th percentile, type S. 

Table B-2. Summary of 238Pu type S intake rates (pCi/d) and dates. 

Start End 50th percentile 84th percentile GSD

01/01/1968 12/31/1971 42.95 246.5 5.74

01/01/1972 12/31/1972 764.7 2,394 3.13

01/01/1973 12/31/1974 72.28 301.3 4.17

01/01/1975 12/31/1981 5.235 44.34 8.47

01/01/1982 12/31/1988 1.818 15.02 8.26

01/01/1989 12/31/1993 9.708 39.21 4.04

01/01/1994 12/31/2008 0.717 4.72 6.58

Figure B-34. Predicted 239Pu bioassay results calculated using IMBA-derived 

239Pu intake rates (line) compared with bioassay results (dots), 1944 to 1945, 50th 

percentile, type M. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 59 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-35. Predicted 239Pu bioassay results calculated using IMBA-derived 

239Pu intake rates (line) compared with bioassay results (dots), 1946, 50th 

percentile, type M. 

Figure B-36. Predicted 239Pu bioassay results calculated using IMBA-derived 

239Pu intake rates (line) compared with bioassay results (dots), 1947, 50th 

percentile, type M. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 60 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-37. Predicted 239Pu bioassay results calculated using IMBA-derived 

239Pu intake rates (line) compared with bioassay results (dots), 1954 to 1956, 50th 

percentile, type M. 

Figure B-38. Predicted 239Pu bioassay results calculated using IMBA-derived 

239Pu intake rates (line) compared with bioassay results (dots), 1957 to 1966, 50th 

percentile, type M. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 61 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-39. Predicted 239Pu bioassay results calculated using IMBA-derived 

239Pu intake rates (line) compared with bioassay results (dots), 1967 to 1972, 50th 

percentile, type M. 

Figure B-40. Predicted 239Pu bioassay results calculated using IMBA-derived 

239Pu intake rates (line) compared with bioassay results (dots), 1973 to 1975, 50th 

percentile, type M. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 62 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-41. Predicted 239Pu bioassay results calculated using IMBA-derived 

239Pu intake rates (line) compared with bioassay results (dots), 1976 to 1993, 50th 

percentile, type M. 

Figure B-42. Predicted 239Pu bioassay results calculated using IMBA-derived 

239Pu intake rates (line) compared with bioassay results (dots), 1994 to 2008, 50th 

percentile, type M. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 63 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-43. Predicted 239Pu bioassay results calculated using IMBA-derived 

239Pu intake rates (line) compared with bioassay results (dots), 1944 to 1945, 84th 

percentile, type M. 

Figure B-44. Predicted 239Pu bioassay results calculated using IMBA-derived 

239Pu intake rates (line) compared with bioassay results (dots), 1946, 84th 

percentile, type M. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 64 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-45. Predicted 239Pu bioassay results calculated using IMBA-derived 

239Pu intake rates (line) compared with bioassay results (dots), 1947 to 1954, 84th 

percentile, type M. 

Figure B-46. Predicted 239Pu bioassay results calculated using IMBA-derived 

239Pu intake rates (line) compared with bioassay results (dots), 1955 to 1956, 84th

percentile, type M. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 65 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-47. Predicted 239Pu bioassay results calculated using IMBA-derived 

239Pu intake rates (line) compared with bioassay results (dots), 1957 to 1966, 84th 

percentile, type M. 

Figure B-48. Predicted 239Pu bioassay results calculated using IMBA-derived 

239Pu intake rates (line) compared with bioassay results (dots), 1967 to 1972, 84th 

percentile, type M. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 66 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-49. Predicted 239Pu bioassay results calculated using IMBA-derived 

239Pu intake rates (line) compared with bioassay results (dots), 1973 to 1975, 84th 

percentile, type M. 

Figure B-50. Predicted 239Pu bioassay results calculated using IMBA-derived 

239Pu intake rates (line) compared with bioassay results (dots), 1976 to 1993, 84th 

percentile, type M. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 67 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-51. Predicted 239Pu bioassay results calculated using IMBA-derived 

239Pu intake rates (line) compared with bioassay results (dots), 1994 to 2008, 84th 

percentile, type M. 

Figure B-52. Predicted 239Pu bioassay results calculated using IMBA-derived 

239Pu intake rates (line) compared with bioassay results (dots) from all intakes, 

50th percentile, type M. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 68 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-53. Predicted 239Pu bioassay results calculated using IMBA-derived 

239Pu intake rates (line) compared with bioassay results (dots) from all intakes, 

84th percentile, type M. 

Table B-3. Summary of 239Pu type M intake rates (pCi/d) and dates. 

Start End 50th percentile 84th percentile GSD

01/01/1944 12/31/1945 247.9 1,253 5.05

01/01/1946 12/31/1946 94.53 590 6.24

01/01/1947 12/31/1953 10.46 53.96 5.16

01/01/1954 12/31/1954 3.146 53.96 17.15

01/01/1955 12/31/1956 3.146 39.05 12.41

01/01/1957 12/31/1966 0.379 4.62 12.19

01/01/1967 12/31/1972 3.267 15.71 4.81

01/01/1973 12/31/1975 1.535 9.54 6.21

01/01/1976 12/31/1993 0.164 1.12 6.83

01/01/1994 12/31/2008 0.013 0.15 12.20

Figure B-54. Predicted 239Pu urinalysis bioassay results calculated using IMBAderived 239Pu intake rates (line) compared with bioassay results (dots), 1944 to 

1945, 50th percentile, type S. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 69 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-55. Predicted 239Pu urinalysis bioassay results calculated using IMBAderived 239Pu intake rates (line) compared with bioassay results (dots), 1946, 50th 

percentile, type S. 

Figure B-56. Predicted 239Pu urinalysis bioassay results calculated using IMBAderived 239Pu intake rates (line) compared with bioassay results (dots), 1947 to 

1953, 50th percentile, type S. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 70 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-57. Predicted 239Pu urinalysis bioassay results calculated using IMBAderived 239Pu intake rates (line) compared with bioassay results (dots), 1954 to 

1956, 50th percentile, type S. 

Figure B-58. Predicted 239Pu urinalysis bioassay results calculated using IMBAderived 239Pu intake rates (line) compared with bioassay results (dots), 1957 to 

1966, 50th percentile, type S. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 71 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-59. Predicted 239

Pu urinalysis bioassay results calculated using IMBAderived 239Pu intake rates (line) compared with bioassay results (dots), 1967 to 

1972, 50th percentile, type S. 

Figure B-60. Predicted 239Pu urinalysis bioassay results calculated using IMBAderived 239Pu intake rates (line) compared with bioassay results (dots), 1973 to 

1975, 50th percentile, type S. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 72 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-61. Predicted 239Pu urinalysis bioassay results calculated using IMBAderived 239Pu intake rates (line) compared with bioassay results (dots), 1976 to 

1993, 50th percentile, type S. 

Figure B-62. Predicted 239Pu urinalysis bioassay results calculated using IMBAderived 239Pu intake rates (line) compared with bioassay results (dots), 1994 to 

2008, 50th percentile, type S. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 73 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-63. Predicted 239Pu urinalysis bioassay results calculated using IMBAderived 239Pu intake rates (line) compared with bioassay results (dots), 1944 to 

1945, 84th percentile, type S. 

Figure B-64. Predicted 239Pu urinalysis bioassay results calculated using IMBAderived 239Pu intake rates (line) compared with bioassay results (dots), 1946, 84th 

percentile, type S. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 74 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-65. Predicted 239Pu urinalysis bioassay results calculated using IMBAderived 239Pu intake rates (line) compared with bioassay results (dots), 1947 to 

1954, 84th percentile, type S. 

Figure B-66. Predicted 239Pu urinalysis bioassay results calculated using IMBAderived 239Pu intake rates (line) compared with bioassay results (dots), 1955 to 

1956, 84th percentile, type S. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 75 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-67. Predicted 239Pu urinalysis bioassay results calculated using IMBAderived 239Pu intake rates (line) compared with bioassay results (dots), 1957 to 

1966, 84th percentile, type S. 

Figure B-68. Predicted 239Pu urinalysis bioassay results calculated using IMBAderived 239Pu intake rates (line) compared with bioassay results (dots), 1967 to 

1972, 84th percentile, type S. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 76 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-69. Predicted 239Pu urinalysis bioassay results calculated using IMBAderived 239Pu intake rates (line) compared with bioassay results (dots), 1973 to 

1975, 84th percentile, type S. 

Figure B-70. Predicted 239Pu urinalysis bioassay results calculated using IMBAderived 239Pu intake rates (line) compared with bioassay results (dots), 1976 to 

1993, 84th percentile, type S. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 77 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-71. Predicted 239Pu urinalysis bioassay results calculated using IMBAderived 239Pu intake rates (line) compared with bioassay results (dots), 1994 to 

2008, 84th percentile, type S. 

Figure B-72. Predicted 239Pu urinalysis bioassay results calculated using IMBAderived 239Pu intake rates (line) compared with bioassay results (dots) from all 

intakes, 50th percentile, type S. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 78 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-73. Predicted 239Pu urinalysis bioassay results calculated using IMBAderived 239Pu intake rates (line) compared with bioassay results (dots) from all 

intakes, 84th percentile, type S. 

Table B-4. Summary of 239

Pu type S urinalysis-based intake rates 

(pCi/d) and dates. 

Start End 50th percentile 84th percentile GSD

01/01/1944 12/31/1945 8,651 43,270 5.05

01/01/1946 12/31/1946 5,125 31,990 6.24

01/01/1947 12/31/1953 200.2 975 4.87

01/01/1954 12/31/1954 87.71 975 11.12

01/01/1955 12/31/1956 87.71 1,342 15.30

01/01/1957 12/31/1966 6.27 74.67 11.91

01/01/1967 12/31/1972 73.47 339.2 4.62

01/01/1973 12/31/1975 40.56 257 6.34

01/01/1976 12/31/1993 2.303 14.51 6.30

01/01/1994 12/31/2008 0.1402 1.798 12.82

Figure B-74. Predicted 239Pu lung burden bioassay results calculated using IMBAderived 239Pu intake rates (line) compared with bioassay results (dots), 1969 to 

1971, 50th percentile, type S. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 79 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-75. Predicted 239Pu lung burden bioassay results calculated using IMBAderived 239Pu intake rates (line) compared with bioassay results (dots), 1972 to 

1974, 50th percentile, type S. 

Figure B-76. Predicted 239Pu lung burden bioassay results calculated using IMBAderived 239Pu intake rates (line) compared with bioassay results (dots), 1975, 50th 

percentile, type S. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 80 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-77. Predicted 239Pu lung burden bioassay results calculated using IMBAderived 239Pu intake rates (line) compared with bioassay results (dots), 1976 to 

1977, 50th percentile, type S. 

Figure B-78. Predicted 239Pu lung burden bioassay results calculated using IMBAderived 239Pu intake rates (line) compared with bioassay results (dots), 1978 to 

1979, 50th percentile, type S. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 81 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-79. Predicted 239Pu lung burden bioassay results calculated using IMBAderived 239Pu intake rates (line) compared with bioassay results (dots), 1969 to 

1971, 84th percentile, type S. 

Figure B-80. Predicted 239Pu lung burden bioassay results calculated using IMBAderived 239Pu intake rates (line) compared with bioassay results (dots), 1972 to 

1974, 84th percentile, type S. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 82 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-81. Predicted 239Pu lung burden bioassay results calculated using IMBAderived 239Pu intake rates (line) compared with bioassay results (dots), 1975, 84th 

percentile, type S. 

Figure B-82. Predicted 239Pu lung burden bioassay results calculated using IMBAderived 239Pu intake rates (line) compared with bioassay results (dots), 1976 to 

1977, 84th percentile, type S. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 83 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-83. Predicted 239Pu lung burden bioassay results calculated using IMBAderived 239Pu intake rates (line) compared with bioassay results (dots), 1978 to 

1979, 84th percentile, type S. 

Table B-5. Summary of 239Pu type S lung burden-based intake rates 

(pCi/d) and dates. 

Start End 50th percentile 84th percentile GSD

01/01/1969 12/31/1971 27.66 118.9 4.30

01/01/1972 12/31/1974 29.43 132.5 4.50

01/01/1975 12/31/1975 505.4 942.5 1.86

01/01/1976 12/31/1977 96.07 339.8 3.54

01/01/1978 12/31/1979 19.55 101.7 5.20

Figure B-84. Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1944 to 1945, 50th percentile, type SS. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 84 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-85. Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1946, 50th percentile, type SS. 

Figure B-86. Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1947 to 1953, 50th percentile, type SS. 

Figure B-87. Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1954 to 1956, 50th percentile, type SS. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 85 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-88. Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1957 to 1966, 50th percentile, type SS. 

Figure B-89. Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1967 to 1972, 50th percentile, type SS. 

Figure B-90. Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1973 to 1975, 50th percentile, type SS. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 86 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-91. Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1976 to 1993, 50th percentile, type SS. 

Figure B-92. Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1994 to 2008, 50th percentile, type SS. 

Figure B-93. Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1944 to 1945, 84th percentile, type SS. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 87 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-94. Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1946, 84th percentile, type SS. 

Figure B-95. Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1947 to 1954, 84th percentile, type SS. 

Figure B-96. Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1955 to 1956, 84th percentile, type SS. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 88 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-97. Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1957 to 1966, 84th percentile, type SS. 

Figure B-98. Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1967 to 1972, 84th percentile, type SS. 

Figure B-99. Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1973 to 1975, 84th percentile, type SS. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 89 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-100. Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1976 to 1993, 84th percentile, type SS. 

Figure B-101. Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots), 1994 to 2008, 84th percentile, type SS. 

Figure B-102. Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots) from all intakes, 50th percentile, type SS. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 90 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-103. Predicted 239Pu urinalysis bioassay results calculated using IDOT-derived 239Pu intake 

rates (line) compared with bioassay results (dots) from all intakes, 84th percentile, type SS. 

Table B-6. Summary of 239Pu type SS urinalysis-based intake rates 

(pCi/d) and dates. 

Start End 50th percentile 84th percentile GSD

01/01/1944 12/31/1945 51,900 262,000 5.05

01/01/1946 12/31/1946 11,200 69,600 6.21

01/01/1947 12/31/1953 1,460 7,490 5.13

01/01/1954 12/31/1954 437 7,490 17.14

01/01/1955 12/31/1956 437 5,270 12.06

01/01/1957 12/31/1966 52 635 12.21

01/01/1967 12/31/1972 452 2,180 4.82

01/01/1973 12/31/1975 214 1,330 6.21

01/01/1976 12/31/1993 21.1 144 6.82

01/01/1994 12/31/2008 1.69 20 11.83

Figure B-104. Predicted 239Pu lung burden bioassay results calculated using IDOT-derived 239Pu 

intake rates (line) compared with bioassay results (dots), 1969 to 1971, 50th percentile, type SS. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 91 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-105. Predicted 239Pu lung burden bioassay results calculated using IDOT-derived 239Pu 

intake rates (line) compared with bioassay results (dots), 1972 to 1974, 50th percentile, type SS. 

Figure B-106. Predicted 239Pu lung burden bioassay results calculated using IDOT-derived 239Pu 

intake rates (line) compared with bioassay results (dots), 1975, 50th percentile, type SS. 

Figure B-107. Predicted 239Pu lung burden bioassay results calculated using IDOT-derived 239Pu 

intake rates (line) compared with bioassay results (dots), 1976 to 1977, 50th percentile, type SS. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 92 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-108. Predicted 239Pu lung burden bioassay results calculated using IDOT-derived 239Pu 

intake rates (line) compared with bioassay results (dots), 1978 to 1979, 50th percentile, type SS. 

Figure B-109. Predicted 239Pu lung burden bioassay results calculated using IDOT-derived 239Pu 

intake rates (line) compared with bioassay results (dots), 1969 to 1971, 84th percentile, type SS. 

Figure B-110. Predicted 239Pu lung burden bioassay results calculated using IDOT-derived 239Pu 

intake rates (line) compared with bioassay results (dots), 1972 to 1974, 84th percentile, type SS. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 93 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-111. Predicted 239Pu lung burden bioassay results calculated using IDOT-derived 239Pu 

intake rates (line) compared with bioassay results (dots), 1975, 84th percentile, type SS. 

Figure B-112. Predicted 239Pu lung burden bioassay results calculated using IDOT-derived 239Pu 

intake rates (line) compared with bioassay results (dots), 1976 to 1977, 84th percentile, type SS. 

Figure B-113. Predicted 239Pu lung burden bioassay results calculated using IDOT-derived 239Pu 

intake rates (line) compared with bioassay results (dots), 1978 to 1979, 84th percentile, type SS. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 94 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Table B-7. Summary of 239Pu type SS lung burden-based intake 

rates (pCi/d) and dates. 

Start End 50th percentile 84th percentile GSD

01/01/1969 12/31/1971 24.4 105 4.30

01/01/1972 12/31/1974 25.9 117 4.52

01/01/1975 12/31/1975 447 834 1.87

01/01/1976 12/31/1977 83.9 297 3.54

01/01/1978 12/31/1979 17.1 88.8 5.19

Figure B-114. Predicted polonium bioassay results calculated using IMBA-derived 

polonium intake rates (line) compared with bioassay results (dots) from all 

intakes, 50th percentile, type F. 

Figure B-115. Predicted polonium bioassay results calculated using IMBA-derived 

polonium intake rates (line) compared with bioassay results (dots) from all 

intakes, 84th percentile, type F. 

Table B-8. Summary of polonium type F intake rates (pCi/d) and dates. 

Start End 50th percentile 84th percentile GSD

01/01/1947 03/31/1949 592.8 4,126 6.96

04/01/1949 12/31/1956 592.8 1,587 2.68
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 95 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-116. Predicted polonium bioassay results calculated using IMBA-derived 

polonium intake rates (line) compared with bioassay results (dots) from all 

intakes, 50th percentile, type M. 

Figure B-117. Predicted polonium bioassay results calculated using IMBA-derived 

polonium intake rates (line) compared with bioassay results (dots) from all 

intakes, 84th percentile, type M. 

Table B-9. Summary of polonium type M intake rates (pCi/d) and dates. 

Start End 50th percentile 84th percentile GSD

01/01/1947 03/31/1949 2,013 14,120 7.01

04/01/1949 12/31/1956 2,013 5,346 2.65
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 96 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-118. Predicted polonium acute intake bioassay fit calculated using an 

IMBA-derived polonium intake rate (line) compared with bioassay results (dots) 

for individual “A,” type F. 

Figure B-119. Predicted polonium acute intake bioassay fit calculated using an 

IMBA-derived polonium intake rate (line) compared with bioassay results (dots) 

for individual “B,” type F. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 97 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-120. Predicted polonium acute intake bioassay fit calculated using an 

IMBA-derived polonium intake rate (line) compared with bioassay results (dots) 

for individual “C,” type F. 

Figure B-121. Predicted polonium acute intake bioassay fit calculated using an 

IMBA-derived polonium intake rate (line) compared with bioassay results (dots) 

for individual “D,” type F. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 98 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-122. Predicted polonium acute intake bioassay fit calculated using an 

IMBA-derived polonium intake rate (line) compared with bioassay results (dots) 

for individual “E,” type F. 

Figure B-123. Predicted polonium acute intake bioassay fit calculated using an 

IMBA-derived polonium intake rate (line) compared with bioassay results (dots) 

for individual “F,” type F. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 99 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-124. Predicted polonium acute intake bioassay fit calculated using an 

IMBA-derived polonium intake rate (line) compared with bioassay results (dots) 

for individual “G,” type F. 

Figure B-125. Predicted polonium acute intake bioassay fit calculated using an 

IMBA-derived polonium intake rate (line) compared with bioassay results (dots) 

for individual “A,” type M. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 100 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-126. Predicted polonium acute intake bioassay fit calculated using an 

IMBA-derived polonium intake rate (line) compared with bioassay results (dots) 

for individual “B,” type M. 

Figure B-127. Predicted polonium acute intake bioassay fit calculated using an 

IMBA-derived polonium intake rate (line) compared with bioassay results (dots) 

for individual “C,” type M. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 101 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-128. Predicted polonium acute intake bioassay fit calculated using an 

IMBA-derived polonium intake rate (line) compared with bioassay results (dots) 

for individual “D,” type M. 

Figure B-129. Predicted polonium acute intake bioassay fit calculated using an 

IMBA-derived polonium intake rate (line) compared with bioassay results (dots) 

for individual “E,” type M. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 102 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-130. Predicted polonium acute intake bioassay fit calculated using an 

IMBA-derived polonium intake rate (line) compared with bioassay results (dots) 

for individual “F,” type M. 

Figure B-131. Predicted polonium acute intake bioassay fit calculated using an 

IMBA-derived polonium intake rate (line) compared with bioassay results (dots) 

for individual “G,” type M. 

Table B-10. Summary of polonium acute intakes (pCi) type 

F and M. 

Individual Type F Type M

A 1.07E+06 4.55E+06

B 1.06E+07 4.22E+07

C 2.85E+06 1.21E+07

D 2.61E+06 1.12E+07

E 6.44E+06 2.56E+07

F 2.16E+06 9.30E+06

G 1.29E+06 5.36E+06

GM 2.84E+06 1.19E+07
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 103 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-132. Predicted uranium bioassay results calculated using IMBA-derived 

uranium intake rates (line) compared with bioassay results (dots) from all intakes, 

50th percentile, type F. 

Figure B-133. Predicted uranium bioassay results calculated using IMBA-derived 

uranium intake rates (line) compared with bioassay results (dots) from all intakes, 

84th percentile, type F. 

Table B-11. Summary of uranium type F intake rates (pCi/d) and dates. 

Start End 50th percentile 84th percentile GSD

01/01/1950 12/31/1955 21.28 67.25 3.16

01/01/1956 12/31/1957 5.358 17.99 3.36

01/01/1958 12/31/1965 1.981 9.535 4.81

01/01/1966 12/31/1973 0.9086 6.218 6.84

01/01/1974 12/31/1982 0.2270 2.567 11.31

01/01/1983 12/31/1989 1.526 6.768 4.44

01/01/1990 12/31/2008 0.201 0.8091 4.03

01/01/2001 12/31/2001 0.818 1.794 2.19

a. Note: the 2001 intake is additive to the 1990–2008 intake.
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 104 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-134. Predicted uranium bioassay results calculated using IMBA-derived 

uranium intake rates (line) compared with bioassay results (dots) from all intakes, 

50th percentile, type M. 

Figure B-135. Predicted uranium bioassay results calculated using IMBA-derived 

uranium intake rates (line) compared with bioassay results (dots) from all intakes, 

84th percentile, type M. 

Table B-12. Summary of uranium type M intake rates (pCi/d) and dates. 

Start End 50th percentile 84th percentile GSD

01/01/1950 12/31/1955 88.72 279.9 3.15

01/01/1956 12/31/1957 15.96 53.6 3.36

01/01/1958 12/31/1965 7.946 38.94 4.90

01/01/1966 12/31/1973 3.528 24.8 7.03

01/01/1974 12/31/1982 1.029 10.91 10.60

01/01/1983 12/31/1989 6.285 27.74 4.41

01/01/1990 12/31/2008 0.7555 3.065 4.06

01/01/2001 12/31/2001 3.944 8.644 2.19

a. Note: the 2001 intake is additive to the 1990–2008 intake.
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 105 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-136. Predicted uranium bioassay results calculated using IMBA-derived 

uranium intake rates (line) compared with bioassay results (dots), 1950 to 1955, 

50th percentile, type S. 

Figure B-137. Predicted uranium bioassay results calculated using IMBA-derived 

uranium intake rates (line) compared with bioassay results (dots), 1956 to 1957, 

50th percentile, type S. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 106 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-138. Predicted uranium bioassay results calculated using IMBA-derived 

uranium intake rates (line) compared with bioassay results (dots), 1958 to 1965, 

50th percentile, type S. 

Figure B-139. Predicted uranium bioassay results calculated using IMBA-derived 

uranium intake rates (line) compared with bioassay results (dots), 1966 to 1973, 

50th percentile, type S. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 107 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-140. Predicted uranium bioassay results calculated using IMBA-derived 

uranium intake rates (line) compared with bioassay results (dots), 1974 to 1982, 

50th percentile, type S. 

Figure B-141. Predicted uranium bioassay results calculated using IMBA-derived 

uranium intake rates (line) compared with bioassay results (dots), 1983 to 1989, 

50th percentile, type S. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 108 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-142. Predicted uranium bioassay results calculated using IMBA-derived 

uranium intake rates (line) compared with bioassay results (dots), 1990 to 2008, 

50th percentile, type S. 

Figure B-143. Predicted uranium bioassay results calculated using IMBA-derived 

uranium intake rates (line) compared with bioassay results (dots), 1950 to 1955, 

84th percentile, type S. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 109 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-144. Predicted uranium bioassay results calculated using IMBA-derived 

uranium intake rates (line) compared with bioassay results (dots), 1956 and 1957, 

84th percentile, type S. 

Figure B-145. Predicted uranium bioassay results calculated using IMBA-derived 

uranium intake rates (line) compared with bioassay results (dots), 1958 to 1965, 

84th percentile, type S. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 110 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-146. Predicted uranium bioassay results calculated using IMBA-derived 

uranium intake rates (line) compared with bioassay results (dots), 1966 to 1973, 

84th percentile, type S. 

Figure B-147. Predicted uranium bioassay results calculated using IMBA-derived 

uranium intake rates (line) compared with bioassay results (dots), 1974 to 1982, 

84th percentile, type S. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 111 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-148. Predicted uranium bioassay results calculated using IMBA-derived 

uranium intake rates (line) compared with bioassay results (dots), 1983 to 1989, 

84th percentile, type S. 

Figure B-149. Predicted uranium bioassay results calculated using IMBA-derived 

uranium intake rates (line) compared with bioassay results (dots), 1990 to 2008, 

84th percentile, type S. 
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 112 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-150. Predicted uranium bioassay results calculated using IMBA-derived 

uranium intake rates (line) compared with bioassay results (dots), all intake 

periods, 50th percentile, type S. 

Figure B-151. Predicted uranium bioassay results calculated using IMBA-derived 

uranium intake rates (line) compared with bioassay results (dots), all intake 

periods, 84th percentile, type S. 

Table B-13. Summary of uranium type S intake rates (pCi/d) and dates. 

Start End 50th percentile 84th percentile GSD

01/01/1950 12/31/1955 1,520 4,760 3.13

01/01/1956 12/31/1957 655.5 2,125 3.24

01/01/1958 12/31/1965 141 664.5 4.71

01/01/1966 12/31/1973 59.25 390.4 6.59

01/01/1974 12/31/1982 19.66 182.3 9.27

01/01/1983 12/31/1989 104.5 463.5 4.44

01/01/1990 12/31/2008 10.97 50.12 4.57

01/01/2001 12/31/2001 80.980 109.5 1.35

a. Note: The 2001 intake is additive to the 1990–2008 intake.
Document No. ORAUT-OTIB-0062 Revision No. 01 Effective Date: 09/01/2020 Page 113 of 113

ATTACHMENT B

CO-EXPOSURE DATA FIGURES

Figure B-152. Predicted cesium bioassay results calculated using IMBA-derived 

cesium intake rates (line) compared with bioassay results (dots) from all intakes, 

50th percentile, type F. 

Figure B-153. Predicted cesium bioassay results calculated using IMBA-derived 

cesium intake rates (line) compared with bioassay results (dots) from all intakes, 

84th percentile, type F. 

Table B-14. Summary of type F 137Cs intake rates (pCi/d) and dates. 

Start End 50th percentile 84th percentile GSD

01/01/1970 12/31/1974 185.5 540.9 2.92

01/01/1975 12/31/1979 130.7 428.9 3.28

01/01/1980 12/31/1984 69.47 136.2 1.96

01/01/1985 12/31/1988 47.36 99.75 2.11

01/01/1990 12/31/1993 30.16 62.85 2.08